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Abstract 
 
 
 Highly effective, targeted therapies against cancer would revolutionize the way 
people recover from this devastating illness.  Gone would be the lingering side effects of 
the current non-specific treatments and in their place would be faster recovery times, 
better quality of life both during and after treatment, and less ambiguity about whether or 
not treatment was effective.  This concept will elude modern medicine until treatments 
can be tailored to the patient’s individual and unique disease.  This concept of a transient, 
targeted, and tailored vehicle aimed at cancer cells lends itself to the use of replication 
deficient retroviral gene therapy vectors with interchangeable receptor binding sites.  
These vectors may be used separately or in combination with each other to ensure 
maximum delivery of a suicide gene only to cancerous cells involved with the primary 
tumor as well as those equally dangerous metastatic cells. 
 
 Recently, a prototype retroviral vector incorporating the short peptide Somatostatin in 
place of its natural receptor binding site has been developed.  The design of this chimeric 
envelope protein has the potential to make the insertion of varied receptor binding sites a 
simple and efficient process.  The goal of my studies was to learn more about the 
potential of this design by taking steps towards challenging its ligand capacity, both in 
size and secondary structure, and improving its interaction with the target cell.   
 
 My studies indicate that the peptide ligand Stromal Derived Factor-1α (lysine 22 
through lysine 89) is not a good candidate for use with this chimeric design.  They also 
show that only certain modifications within the Moloney Murine Leukemia Virus heparin 
binding motif can be tolerated.  Supplemental studies point out that (1) the removal of an 
MluI site at the CMV promoter N-terminus may enhance promoter function, (2) TransIT 
(Mirus) is an effective reagent for transfection of DNA into the MDA-MB-231 breast 
cancer cell line, and (3) a eukaryotic α-complementation assay is not sensitive enough to 
detect cell-cell fusion at levels below that of the wild type MoMLV envelope with its 
natural receptor.  While much investigation remains to be done, these observations will 
help pave the way to the development of effective retroviral vectors for cancer therapy.   
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Chapter 1.  Introduction 
 
 
Brief Overview of Gene Therapy  
 
 It has long been conceived that genetic defects may be repaired by the delivery of a 
gene that can effectively produce a protein allowing cells to function normally or, as in 
the case of cancer therapies, results in tumor cell death.  This concept is known as gene 
therapy and faces several hindrances that must be considered before any gene may 
successfully be delivered.  First, the host immune system presents several barriers 
occurring at different stages of gene delivery.  Not only will the vehicle or vector itself 
likely be immunogenic, but any new gene product may also elicit an unfavorable immune 
response.  Further challenges are presented by the need to deliver a gene into a specific 
cell and expression of this new protein at levels required to produce a therapeutic effect.   
 
 Although several methods have successfully been utilized to deliver genes to cells ex 
vivo, there are very few viable options for in vivo gene therapy.  Gene therapy using 
retroviral vectors was conceived in the early 1980’s and has demonstrated a considerable 
success rate in clinical trials of ex vivo gene delivery to progenitor cells of the bone 
marrow [2-5].  The family Retroviridae is divided into two subfamilies, Orthoretrovirinae 
and Spumavirinae.  The subfamily Orthoretrovirinae is further broken down into six 
types: Alpharetrovirus (prototypically represented by the Avian Leukosis Virus, ALV), 
Betaretrovirus (Mouse Mammary Tumor Virus, MMTV), Gammaretrovirus (Murine 
Leukemia Virus, MLV), Deltaretrovirus (Bovine Leukemia Virus, BLV), 
Epislonretrovirus (Walleye Dermal Sarcoma Virus, WDSV), and Lentivirus (Human 
Immunodeficiency Virus Type I, HIV-1), which are defined by their method of host cell 
entry.   
 
 The retroviral genome consists of two positively oriented, single strands of RNA.  
The alpha-, beta-, and gammaretroviruses have simple genomes coding for only the main 
structural and enzymatic genes gag, pol, and env while the others have complex genomes 
which include non-structural accessory genes which affect pathogenesis and/or gene 
expression of viral proteins.  Retroviruses attach to their host cell using their surface 
protein which undergoes conformational changes that mediate host cell and virion 
membrane fusion thus allowing transfer of the viral core to the host cell cytoplasm.  It is 
from within this viral core that the viral reverse transcriptase transcribes the genome from 
RNA to DNA.  These two strands of DNA come together end to end and are coupled with 
the viral integrase to form a linear preintegration complex which either traverses the 
nuclear membrane, as in the case of lentiviruses, or takes advantage of the nuclear 
breakdown during cell division to be inserted into the host cell genome.  This integrated 
genome is called the provirus and consists of the viral genome flanked by long terminal 
repeats (LTRs) made up of unique 3’ and 5’ regions and a repeat region duplicated during 
the reverse transcription process.  This provirus is then transcribed by the host cell RNA 
polymerase II into full length RNA transcripts which are either transported as messenger 
RNA (mRNA) into the cytoplasm or spliced within the nucleus to create mRNA for the 
envelope polyprotein and then transported into the cytoplasm.  In the cytoplasm, the full 
1 
length mRNA are first translated into precursor polyproteins, Gag and Gag-Pol, which 
are cleaved into the various structural (capsid, matrix, nucleocapsid) and enzymatic 
(protease, reverse transcriptase, integrase) proteins necessary for particle production and 
then, as particles become available, are packaged as viral genomes with the protease, 
reverse transcriptase, and integrase proteins.  The envelope mRNA is directed to the 
endoplasmic reticulium where it is translated and processed.  This process will be further 
discussed in the next section. 
 
 
Moloney Murine Leukemia Virus as a Retroviral Vector  
 
 The MLV group or viruses consists of several subtypes which differ in host range: 
amphotropic, ecotropic, polytropic, xenotropic, and 10A1, based on their receptor 
preference [6].  Moloney Murine Leukemia Virus (MoMLV), an ecotropic MLV, has 
been a key player in the quest to develop an effective vector for gene therapy [7] and has 
been studied extensively in an effort to overcome the difficulty presented in targeting 
these vectors to specific cell types.  MoMLV offers a unique starting point in the sense 
that its host range does not extend beyond the rodent cells which express its receptor, a 
cationic amino acid transporter known by several different names (Slc7a1, ATRC-1, 
mCAT-1, Rec-1, and Rev-1).  Homologs of this receptor are present in other species, but 
do not serve as ecotropic MLV receptors due to sequence variation in the virus binding 
site [8-11].  Three receptor residues have been shown to provide the most critical 
contribution to virus binding:  lysine 234, tyrosine 235 and glutamic acid 237, only the 
first residue of which is conserved in the amino acid transporter of non-rodent species 
[10, 12].  Therefore it is unlikely humans will have previously been exposed to this virus 
and have developed defenses against it.   
 
 Although many attempts at targeting using chimeric MoMLV virions have been made 
in the past and some reports of success have been made, none of these claims have been 
substantiated by other investigators and this goal remains unachieved [13].  Many of 
these attempts have, however, answered critical questions.  First and foremost, the 
question of MoMLV host range expansion was addressed and it was discovered that 
expansions are possible through mutations and insertions made in the surface (SU) 
subunit of the MoMLV envelope protein [14-21].  Furthermore, any mutations or 
additions in this region must be made in such a way as not to disturb the structural 
integrity and thus the function of this protein [22-31].   
 
 Retroviral envelope mRNA is derived from an alternative splicing event which 
removes the gag and pol genes as discussed earlier.  The resulting mRNA is translated in 
the endoplasmic reticulum where the resulting proteins associate as trimers which are 
transported to the Golgi for glycosylation and furin-like protease cleavage into two 
portions: the SU subunit mentioned in the above paragraph and the transmembrane (TM) 
subunit which are linked by disulfide bonds [32].  Cleavage of SU from TM is not a 
prerequisite for the production of infectious viral particles [33].  TM is further cleaved by 
the viral protease to activate fusion after budding occurs [34-37].  The MLV SU consists 
of a receptor binding domain (RBD), a hypervariable proline rich region (PRR), and a C-
2 
terminal domain (CTD).  The MLV RBD has been determined to include three variable 
regions responsible for its variance in receptor tropism, termed variable regions A, B, and 
C (VRA, VRB, and VRC); within those regions are hydrophilic loops created by 
disulfide bonds that also affect receptor binding [38-43].  Once SU binds its receptor, it 
undergoes conformational changes which expose the fusion peptide and allow transfer of 
the viral genome from the endosome into the host cell cytoplasm [44].  Figure 1-1 shows 
a schematic representation of the MLV envelope protein.  
 
 Extensive genetic analysis of the MoMLV RBD has revealed the receptor binding 
sequences within it.  Aspartic acid 84 (D84) is the most important residue involved in 
virus binding to its natural receptor and the fourteen residue disulphide-bonded loop 
containing D84 is thought to be the receptor binding sequence (RBS).  A D84 changed to 
lysine (D84K) mutation is the only known single change in the envelope protein that 
completely abrogates virus binding to the natural receptor [42, 45].  Virions bearing a 
D84K mutated envelope are non-infectious [42], but infection can be rescued fully by 
using a receptor with a complementary lysine 234 to aspartic acid (K234D)change [12], 
supporting the thought that the RBS lies within the disulfide-bonded loop from residues 
72 - 85 (numbered from the mature N-terminus of the MoMLV envelope protein). 
 
 In our research group, Ryu and coworkers showed that while insertion of the peptide 
ligand IL-13 sequence into the amino-terminus (N-terminus) or the PRR of SU did not 
give infection, the reason for loss of function differed with the position of the insertion 
[31].  Insertion in the N-terminus blocked entry immediately after virus binding whereas 
the PRR insertion blocked entry after membrane fusion began, after exposure of the 
fusion peptide but before stable fusion pores were formed.  These authors proposed that 
one way to overcome these blocks to entry would be to use a new design for modifying 
the MoMLV envelope protein in which the natural RBS, those specific residues that 
contact the natural receptor during virus attachment, was replaced by a peptide ligand 
sequence. 
 
 To test their proposal, two of these authors (L. Albritton and F. Li) replaced the RBS 
with somatostatin (Sst), a short peptide structurally homologous to the RBS sequence 
[46].  To accomplish this, amino acids 72 through 85 were first replaced by a RBS 
deletion sequence consisting of a tyrosine-alanine-serine (YAS) linker sequence termed 
del RBS which encodes at its center an MluI site.  The Sst peptide was synthesized with 
flanking MluI linkers and inserted into the del RBS sequence.  This chimeric virus 
infected human 293 cells expressing the type 2 somatostatin receptor (SstR2), a G-
coupled protein receptor, at titers greater than 2 x 104 lacZ transducing units per milliliter 
(TU/ml) while control 293 cells lacking the SstR2 cDNA were not infected and murine 
NIH 3T3 cells were infected at titers of less than 10 TU/ml (unpublished observation). 
Thus, their data supported their hypothesis that virions carrying the chimeric Sst/RBS 
envelope protein are the first truly targeted MoMLV-based vector.  
 
 It is commonly accepted that the readily available crystal structure of the Friend 
Murine Leukemia Virus (FrMLV) RBD (RBD (Protein Database (PDB) accession 
number 1AOL) [43, 47] (Figure 1-2) accurately represents the MoMLV RBD, the  
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Figure 1-1.  Schematic Representation of the MLV Envelope Protein.  The Murine 
Leukemia Virus (MLV) envelope protein is made up of two parts, a surface (SU) and a 
transmembrane (TM) subunit, which are separated by furin-like protease cleavage during 
their transit through the host cell Golgi.  The TM domain is further cleaved by the viral 
protease after budding has occurred removing the small p2E or R-peptide and allowing 
for fusion peptide activation.  The SU subunit is made up of three domains: the receptor 
binding domain or RBD, the proline rich region or PRR, and the C-terminal domain or 
CTD.  The RBD has been empirically determined to consist of three regions influencing 
virus receptor binding and attachment: variable regions (VR) A, B, and C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2.  Structural Representation of FrMLV RBD.  Ribbon diagram of the 
FrMLV RBD (Protein Database (PDB) accession number 1AOL) and an enlarged view 
of the portion of RBD containing the fourteen amino acid residues replaced in the Sst 
chimera.  This representation was interpreted by the Molecular Biology Toolkit (MBT) 
Protein Workshop.  The FrMLV D86 amino acid which corresponds to MoMLV D84 is 
indicated in both panels as a ball and stick model.
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rationale being that both MoMLV and FrMLV utilize the same receptor for binding and 
to trigger entry as well as having highly homologous amino acid sequences.  All 
structural considerations during these studies were based on this assumption. 
 
 
Gene Therapy as Treatment for Cancer  
 
 In addition to its usefulness as a therapeutic vehicle for genetic diseases, gene therapy 
may also be used to destroy cancerous cells via delivery of suicide genes designed to 
either increase cell susceptibility to radiation [48], activate cell death upon encountering a 
particular drug [49], or repair damaged cell death mechanisms [50].  The efficacy of gene 
therapy as cancer treatment depends on several factors, but importantly on the ability to 
target cancerous cells for gene delivery.  Without targeting, the concept of treating cancer 
in this way would be no less destructive to the human body than the current treatments of 
radiation, chemotherapy, and surgery [51] which damage normal tissues throughout the 
body to different extents.  For example, radiation and chemotherapy affect actively 
dividing cells and cause side effects such as hair loss, gastrointestinal distress, and fatigue 
[52, 53].  Additionally, excision boundaries extended into known normal tissue during 
surgical removal of tumors could potentially be made more exact through visualization of 
cancerous cells using fluorescent or luminescent protein expression.  There is room for 
improvement in the area of cancer treatment and targeted therapies are one way to 
achieve this goal. 
 
 The phenotypic diversity of breast tumors continues to present a formidable challenge 
in identifying the most effective therapeutic combination for each patient and mortality 
remains unacceptably high despite many advances in the field.  Viral vectors designed 
using the method employed to create the Sst/RBS chimera have the potential benefit of 
rapid interchangeability between peptide ligands allowing for a more patient-specific 
approach to treatment as well as the added ability to deliver a combination of virions 
targeting different receptors on the same breast cancer cells, thus enhancing delivery 
while avoiding competition.  Because the pre-integration complex of integase and the 
reverse transcribed viral cDNA requires breakdown of the nuclear envelope to access the 
host genome, use of the parent virus MoMLV as an anti-cancer agent would afford 
similar levels of specificity to chemotherapy and radiation.  We hope to improve upon 
this current limitation of MoMLV by developing vectors that mediate infection in a 
cancer-specific fashion directly through the use of receptors that are known to be 
upregulated on cancer cells and indirectly through increased attachment to the heparan 
coats cancer cells produce.  It is our belief that the combination of these two attributes 
will serve to increase specificity towards cancerous cells and lessen normal tissue damage 
during treatment.  
6 
Chapter 2.  Materials and Methods 
 
 
Mutagenesis 
 
 Mutations were generated using QuikChange (Stratagene) to introduce mutations that 
encompassed one or two nucleotide changes or ExSite (Stratagene) to introduce large 
stretches (up to approximately seventy nucleotides) of mutated sequence.  
Oligonucleotides for mutagenesis using the QuikChange protocol were homologous to at 
least eighteen nucleotides of the flanking sequence on either side of the mutation site.  
Oligonucleotides for mutagenesis using ExSite oligos were designed as indicated in 
Figure 2-1.  The forward oligonucleotide consisted of sequence both homologous 
(directly following the sequence to be mutated) and non homologous (spanning the 
sequence to be mutated) to the template.  The reverse oligonucleotide was entirely 
homologous to the template sequence immediately preceding the sequence to be mutated.  
However, one chimeric envelope protein described in Chapter 3 (SDF-1α/RBS G) was 
constructed using a modification of the protocol in which both the forward and reverse 
oligonucleotides were designed to introduce a collective sixty-four nucleotides of 
mutated sequence.  Polymerase Chain Reaction (PCR) parameters are outlined in 
Chapters 3 and 4 for each construct.  Following PCR mutagenesis and amplification, all 
products were self-ligated by addition of T4 DNA ligase (New England Biolabs), and 
individual products were propagated in either the E. coli Top10F′ or DH5-α strain. 
 
 
Cell Lines  
 
 The NIH 3T3 mouse fibroblast cell line was maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 8% donor calf serum (DCS).  The 293 
human embryonic kidney cell line and all cell lines derived from 293 cells were 
maintained in DMEM supplemented with 8% fetal bovine serum (FBS) during the 
receptor binding site (RBS) studies.  During the heparin binding site (HBS) studies, the 
H1-BAG cell line was maintained in DMEM supplemented with 8% Fetalplex Animal 
Serum Complex (Gemini BioProducts).  H1-BAG is a stable packaging cell line 
developed via calcium phosphate co-precipitation transfection of 293 cells with the 
pBAG plasmid that contains the E. coli lacZ gene, which codes for the β-galactosidase 
(β-gal) protein, and the viral packaging sequence [33].  All cell lines were cultured at 37 
°C in 9% CO2. 
 
 
Virus Production System  
 
 H1-BAG cells have integrated an unknown number of copies of the pBAG plasmid 
containing the viral packaging or psi sequence from the Gag polyprotein and the lacZ 
gene under the control of the viral 5’ LTR.  All other plasmids used to create viral 
particles contain DNA for the structural and enzymatic components required for particle 
production under the commonly used cytomegalovirus (CMV) promoter and do not  
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Figure 2-1.  Schematic Representation of ExSite Mutagenesis Oligonucleotides.  
ExSite oligonucleotides were designed using either of two methods: Mutated sequence 
located on (A) the forward oligonucleotide only or (B) both the forward and reverse 
oligonucleotides.  There are no gaps in sequence between the forward and reverse 
oligonucleotides using either primer design method, thus the mutations are incorporated 
as the DNA sequence is copied by DNA polymerase and amplified during each round of 
PCR.  The number of nucleotides altered by any primer designed using this method is 
extremely variable.
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contain the packaging sequence.  These plasmids are therefore only transiently available 
for use in the producer cells and are not incorporated into virions.  As a result, the virus is 
replication deficient.  When it enters a host cell, be it through interactions with the 
endogenous or a targeted receptor, its genomic material consisting only of that which 
codes for the packaging sequence and lacZ is integrated into the host cell genome.  No 
structural or enzymatic genes are present, thus no particles can be produced as a result of 
host cell infection; the only genes transcribed are our reporter gene, lacZ, and any 
selection gene present (e.g. neomycin).  Ultimately, these genes will either be replaced by 
or coupled with the gene of interest required for gene therapy. 
 
 
Two-Plasmid System of Retroviral Virus Production.  One plasmid coding for the viral 
genome (5’ and 3’ LTRs, gag, pol, and env genes) minus the packaging sequence in 
pcDNA3 (plasmid number 719, created by former graduate student T. Zavorotinskaya) 
was transiently transfected into H1-BAG cells using the calcium phosphate co-
precipitation method.  The 719 plasmid was later modified by T. Zavorotinskaya as she 
sought to improve virus production by reducing the size of the plasmid by removing the 
neomycin gene from the pcDNA3 portion consequently creating the 752 plasmid 
mentioned in Chapter 4.  The second plasmid required for viral production is the provirus 
within the H1-BAG genome.   
 
 
Three-Plasmid System of Retroviral Virus Production.  In an effort to reduce the 
probability of a homologous recombination event between the 5’ and 3’ portions of the 
structural plasmid and the viral DNA present in the H1-BAG cell genome that might 
result in generation of replication competent recombinant virus, 752 was split into two 
portions by T. Zavorotinskaya; the first, 3240, contained gag, pol, and a truncated env 
within pcDNA3_del Neo.  The second, 3245, contained the env gene and the necessary 
splice donor and splice acceptor sequences from gag and pol respectively.  The 3245 
plasmid was further modified by T. Sullivan who improved the splice donor and splice 
acceptor sequences which enhanced viral envelope production considerably (unpublished 
observation).  This plasmid was termed TS45.  Sequence analysis performed during the 
course of these thesis studies revealed that the 3240 plasmid had more of the env 
sequence than anticipated.  This extraneous sequence was subsequently removed to create 
the GV-6 plasmid described in Appendix A.   
 
 The three-plasmid system required the use of pristine DNA.  Any contaminants 
present in the preparation of these plasmids resulted in reduced particle production.  This 
phenomenon became more pronounced when the level of purity between the transfected 
plasmid preparations varied.  The use of the three-plasmid system was determined to be 
unnecessary after it was determined that no replication competent virus was detected after 
performing a replication competent retrovirus (RCR) marker rescue assay on five 
independent virus productions made using the two plasmid system (200 ml each).  
Briefly, NIH 3T3 cells were infected with a minimum of 1/100th of virus stock volume 
and passaged for three weeks to amplify the amount of virus present.  The harvested 
supernatant was then applied (after filtration and the addition of polybrene, see below) to 
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naïve NIH 3T3-BAG (NIH 3T3 cells containing pBAG in their genome) cells overnight 
in an effort to encourage incorporation of the pBAG genome into viral particles being 
produced.  These freshly infected cells were fed and allowed to produce virus for 48 
hours.  Supernatant from these cells was then applied (again after filtration and the 
addition of ploybrene) to naïve NIH 3T3 cells which were fixed and stained with X-gal 
after 48 hours.  Any cells expressing β-gal activity would indicate transduction of the 
rescued viral genome by RCR.   
 
 
Virus Harvest  
 
 The 24 and 48 hour viral supernatants were filtered through a 0.45 μm filter to 
remove any contaminating cells.  The filtered supernatant was then either pelleted (4 °C, 
30,000 rpm, 1 hr. 30 min., Beckman SW-40 rotor), resuspended in 1 x PBS at 1/225th its 
original volume, and stored at -80 °C prior to Western blot analysis or titer determination. 
 
 
Cell Lysate 
 
 Immediately after the 48 hour viral supernatent was harvested from the transfected 
H1-BAG cells, approximately 1 x 106 cells were incubated with NP-40 lysis buffer (1% 
NP-40, 50 mM Tris [pH 8.8], 150 mM NaCl) containing protease inhibitor cocktail (1:25; 
Sigma P-8340) for 20 minutes at 4 °C and pelleted to remove nuclei and cell debris (4 °C, 
14,000 rpm, 10 min., Eppendorf 5415C centrifuge).  Lysates were treated with 10% SDS 
(0.1% [final]) and stored at -80 °C prior to SDS-PAGE separation.  
 
 
Infection and Titration  
 
 Several 24-well plates were seeded at approximately 1.5 x 105 cells per well if using 
NIH 3T3 cells or 2.3 x 105 cells per well if using 293 or 293 progeny cells and were 
exposed in quadruplicate to 10-fold serial dilutions of viral supernatant containing 8 
μg/μl  Polybrene (1,5-Dimethyl-1,5-diazaundecamethylene polymethobromide, Sigma).  
Cells were fixed 48 hours post exposure with 0.5% Gluteraldehyde (Sigma) and stained 
with X-gal (5-bromo-4-chloro-3-indolyl β-D-galactopyranoside, Invitrogen).  This 
process allowed for the identification of infected cells able to use their acquired β-gal 
activity to break this substrate down into its constituent components, galactose and 5-
bromo-4-chloro-3-hydroxyindole the latter of which is oxidized to become an insoluble 
blue molecule known as 5,5'-dibromo-4,4'-dichloro-indigo.  Titers were determined by 
endpoint dilution unless otherwise noted.  
 
 
SDS-PAGE and Western Blot Analysis  
 
 Viral pellet resuspensions (10 μl) were diluted 1:1 in 2 x SDS loading buffer, 
denatured by boiling for 5 minutes, and run on either an 8% or 10-20% gradient SDS-
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PAGE gel (BioRad).  8% SDS-PAGE gels were cast from a 30% Acrylamide-Bis 
Solution, 29:1 (Bio-Rad) during the SDF-1α/RBS studies and pre-cast (BioRad) during 
the HBS studies.  The separated proteins were then transferred to nitrocellulose (Protran, 
Schleicher & Schuell) and incubated with goat anti-Rauscher-gp70 (1:100, Quality 
Biotech, Inc.) or goat anti-Rauscher-p30 (1:10,000, Quality Biotech, Inc.) antibody for 
one hour followed by horseradish peroxidase (HRP) conjugated mouse anti-goat (1:5000; 
Sigma) antibody for one hour.   
 
 Cell lysates (10 μl) were diluted 1:1 in 2 x SDS loading buffer, boiled for 5 minutes, 
and separated on an 8% SDS-PAGE gel.  The proteins were then transferred to 
nitrocellulose and incubated with goat anti-Rauscher-gp70 followed by mouse anti-
goat/HRP (1:5000, Sigma) as described previously or rabbit anti-actin (1:500, Sigma) 
antibody for one hour followed by goat anti-rabbit/HRP (1:5000, Sigma) antibody for one 
hour.  Blots were developed using a chemiluminescent substrate (SuperSignal, Pierce).
Chapter 3.  Investigation of the Impact Replacing the Putative MoMLV Receptor 
Binding Site with a Large Ligand Has on Envelope Expression and Infection 
 
 
Introduction  
 
 With the success of the Sst/RBS chimeric envelope still fresh in our minds, we set out 
to explore some logical boundaries of the design.  What other ligands might be 
candidates for replacement of this putative MoMLV receptor binding site (RBS)?  What 
constraints might exist?  Would we be limited to ligands of a certain size and/or 
structure?  How large a ligand could we use and how much secondary structure might be 
too much?   
 
 Previous studies had shown that insertion of a fifteen amino acid integrin-binding 
peptide or a single chain antibody fragment between serine 78 (S78) and proline 79 (P79) 
(numbering relative to the amino- or N-terminus) of the MoMLV mature envelope 
protein resulted in exposure of the inserted sequences at the surface of the envelope 
protein and did not interfere with assembly of the chimeric proteins onto virions [20, 21].  
Subsequently, the insertion amino acids lysine 22 (K22) through lysine 89 (K89) of the 
cystine-any amino acid-cystine (CXC) ligand CXCL-12, also known as stromal derived 
factor 1-alpha (SDF-1α), into the MoMLV envelope protein at P79 resulted in the 
production of a virus able to transduce cells expressing the CXCR-4 receptor [54].  Based 
on this information, we designed five chimeric envelope proteins with SDF-1α replacing 
the RBS each with varying degrees of flexible flanking sequence and differences in the 
number of residues replaced within the envelope protein. 
 
 SDF-1α is a CXC chemokine originally associated with bone marrow cell movement 
that has been shown to bind its receptor as a monomer [55-58].  SDF-1α and its G-
coupled protein receptor, CXCR-4 (formerly known as HUMSTER [59], LESTR [60], 
and fusin [61]), have been linked to highly metastatic cancers as well as the migration of 
cancer cells to specific tissues or organs, particularly movement of breast cancer cells to 
the lung and lymph nodes [62-64].  Primary breast tumor cells have been shown to 
express significantly higher levels of CXCR-4 than normal breast epithelial cells [64, 65].  
It is our belief that vectors targeted to breast cancer cells expressing this receptor would 
be an effective tool against primary tumors as well as metastatic cells that have moved to 
other locations in the body such as the brain, bone marrow, and lymphatic system.  
 
 
Materials and Methods 
 
 
Construction of Plasmids for SDF-1α/RBS Chimeras.  Due to the larger size of the 
SDF-1α gene with respect to the limits imposed by oligonucleotide synthesis, the SDF-
1α/RBS plasmids were made in three steps.  All oligonucleotides used to construct and 
amplify these plasmids are listed in Table 3-1.  Table 3-2 lists the PCR parameters used 
to create each vector and amplify the SDF-1α insert. 
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Table 3-1.  Table of Oligos Used to Produce and Identify SDF-1a/RBS and Related Constructs. 
 
Name Sequence 
Fwd A 5’- agcggtggtggctactggggattggagtactctggtggaggaaagcctgtaagcttaagtggattcaggagtacctcgagttaacctccctc acccctc -3’ 
Fwd B 5’- tctggtgggggaaagcctgtaagcttaagtggattcaggagtacctcgagaaggctttaaacaaggaacctttaacctccctcacc -3’ 
Fwd C 5’- tctggtggaaagcctgtaagcttaagtggattcaggagtacctcgagttaacctccctcacccctc-3’ 
Fwd D 5’- agcggtggtggctactggggattggagtactctggtggaggaaaacctgtaagcttaagtggattcaggagtacgaacctttaacctccctc acc -3’ 
Fwd E 5’- tctggtggaaagcctgtaagcttaagtggatccaggagtacgaacctttaacctccctcacc -3’ 
Fwd G 5’- ctcgagaaggcattgaacaaatccagaggctgttccagagactgcgaagaac -3’ 
Rev A, D 5’- gtgggctaacatacataaatctgggg -3’ 
Rev B 5’- atattctagcccccaataagatggtccatggtgggc -3’ 
Rev C, E 5’- tagcccccaataagatggtccatggtgggctaacatacataaatctgggg -3’ 
Rev G 5’- gtactcttggatccacttaagcttacgggcttaccgcggctgctgccccctgagcaacaag -3’ 
Fwd Ins 1 5’- agcttgagctacagatgcccctgcagattcttcgaaagccatgttgccagagccaacgtcaagcatctcaaaattctcaacactc -3’ 
Fwd Ins 2 5’- caaactgtgcccttcagattgtagcccggctgaagaacaacaacagacaagtgtgcattgacccga -3’ 
Rev Ins 1 5’- agcttcgggtcaatgcagacttgtctgttgttgttcttcagccggg -3’ 
Rev Ins 2 5’- ctacaatctgaagggcacagtttggagtgttgagaattttgagatgcttgac -3’ 
Rev Ins 3 5’- gttggctctggcaacatggctttcgaagaatctgcaggggcatctgtagctca -3’ 
SDF-1a Insert Amp Sense 5’- agtctgtaagcttgagctacagatgcc -3’ 
SDF-1a Insert Amp 
Antisense 5’- acacttaagcttcgggtcaatgcacac -3’ 
CXCR4 as 5’- ggctactggagcactcag -3’ 
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Table 3-2.  PCR Mutagenesis Parameters Used to Create SDF-1α Vectors and Amplify the SDF-1α Insert. 
 
Product Name Parameters 
SDF-1α vector A 1 cycle: 95 °C for 2 min.; 18 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C Hold 
SDF-1α vector B 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 50 °C for 1 min., 68 °C for 10 min.;  
20 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C Hold 
SDF-1α vector C 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 50 °C for 1 min., 68 °C for 10 min.;  
20 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C Hold 
SDF-1α vector D 1 cycle: 95 °C for 2 min.; 18 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C Hold 
SDF-1α vector E 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 50 °C for 1 min., 68 °C for 10 min.;  
20 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C Hold 
SDF-1α vector G Round 1 - 1 cycle: 94 °C for 2 min.; 5 cycles: 94 °C for 30 sec., 62 °C for 1 min., 68 °C for 10 min.;  
20 cycles: 94 °C for 30 sec., 67 °C for 1 min., 68 °C for 15 min.; 4 °C Hold 
Round 2 - 95 °C for 2 min.; 25 cycles: 95 °C for 30 sec., 68 °C for 16 min.; 4 °C hold 
SDF-1α Insert 1 cycle: 96 °C for 4 min.; 5 cycles: 96 °C for 1 min., 52 °C for 1 min., 72 °C for 20 min.; 
25 cycles: 96 °C for 1 min., 60 °C for 1 min., 72 °C for 10 min.; 4 °C hold 
 
14 
 First, vectors were created using the slightly modified ExSite mutagenesis protocol 
described in Chapter 2 and the oligonucleotides listed in Table 3-1.  For plasmids SDF-
1α/RBS vector A through E, oligonucleotides were designed to introduce mutations using 
the forward primer.  The SDF-α/RBS vector G oligonucleotides were designed to 
introduce mutations using both the forward and reverse primers.  Primers were applied to 
a 3245 plasmid DNA template (described in Chapter 2), and PCR mutagenesis products 
were purified from randomly picked E. coli strain Top-10F′ colonies, analyzed by 
restriction enzyme digestion for the acquisition of a HindIII site introduced into all the 
vectors during mutagenesis, and verified by DNA sequence analysis. 
 
 Second, amino acids 25 through 75 of SDF-1α (GenBank accession number 
BC039893) [66] were recapitulated by annealing and ligating the two forward and three 
reverse oligonucleotides Fwd Ins 1 and 2 and Rev Ins 1, 2, and 3 listed in Table 3-1.  This 
DNA fragment was PCR amplified using the SDF-1α Insert Amp Sense and Antisense 
oligonucleotides, the product was digested with HindIII, and the resulting, approximately 
200 base pair (bp) fragment, was ligated into the pUC18 HindIII site.  The correct 
sequence was verified by DNA sequence analysis.   
 
 Finally, plasmids SDF-1α/RBS vector A through E and the pUC18-based plasmid 
carrying the SDF-1α insert were digested with HindIII.  The SDF-1α insert was then 
ligated to the vector plasmids to form the SDF-1α/RBS constructs.  All constructs were 
verified by DNA sequence analysis and the final protein sequences of SDF-1α and SDF-
1α/RBS constructs A through G are listed in Table 3-3.  
 
 
Cell Lines and Receptor Plasmid Construction.  The NIH 3T3 and 293 cell lines were 
maintained as described in Chapter 2.  The pcCXCR4 plasmid was constructed by 
subcloning the approximately 2000 bp CXCR-4 cDNA EcoRI fragment from pBABE-
CXCR4-puro (gift from N. Landau) [67] into the EcoRI site of pcDNA3 (Invitrogen) 
under the control of the CMV promoter.  Correct sequence was verified by DNA 
sequence analysis.  Human 293 cells were transiently transfected with the pcCXCR4 
plasmid using FuGene 6 (Roche) lipid transfection reagent at a 6:1 ratio of FuGene 6 (μl) 
to plasmid DNA (μg) and seeded on 24-well plates as described in Chapter 2 at 24 hours 
post transfection.  These cells were referred to as 293/CXCR4 cells. 
 
 
Flow Cytometry.  Approximately 1 x 106 cells were incubated with phycoerythrin (PE) 
conjugated mouse anti-human CXCR-4 (1:25; BD Biosciences) diluted in 1 x PBA for 1 
hour at room temperature.  Calcein AM (0.1 μM [final]; Invitrogen), a live/dead stain 
with similar absorbance and emission wavelengths to FITC, was added during the final 5 
minutes of incubation.  1 x 105 live (Calcein AM positive) cells were analyzed using a 
BD FACScalibur Flow Cytometer.   
 
 
Virus Production, Infection, and Titration.  Virus production was as per the three 
plasmid system described in Chapter 2, using 25 μg of the gag-pol encoding plasmid, 
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Table 3-3.  Alignment of SDF-1α and SDF-1α/RBS Protein Sequences. 
 
 Sequence 
Name MoMLV + flexible linkers SDF-1α MoMLV 
SDF-1α/RBS A …H 5 0 S 1 GGG Y 5 5 WGLEY 6 0 S G G G  K 2 2 PV 2 … 3 L 7 6 KWI QEYLE 8 4  L 8 9 TSLTPR… 
SDF-1α/RBS B …H 5 0 HGPSY 5 5 WG LEY 6 0 S G G G K 2 2 PV…L 7 6 KWIQE YLEKAL NK 8 9  E 8 7 PLTSLTPR… 
SDF-1α/RBS C …H 5 0 HGPSY 5 5 WG L 5 8 S G G K 2 2 PV…L 7 6 K WI Q E Y L E 8 4  L 8 9 TSLTPR… 
SDF-1α/RBS D …H 5 0 S G G G Y 5 5 WGLEY 6 0 S G G G K 2 2 PV…L 7 6 K WI Q E Y 8 2  E 8 7 PLTSLTPR… 
SDF-1α/RBS E … H 5 0 HGPSY 5 5 WG L 5 8 S G G K 2 2 PV…L 7 6 K WI Q E Y 8 2  E 8 7 PLTSLTPR… 
SDF-1α/RBS G P 7 1 CCSGGSS 7 8 RG K 2 2 PV…L 7 6 KWIQE YLEKAL NK 8 9  SRG 8 0 CS RD… 
SDF-1α Insert S25LSYRCPCRFFESHVARANVKHLKILNTPNCALQIVARLKNNNRQVCIDPK75 
 
1Amino acids added to MoMLV protein sequence are in bold face type.  2 Italicized letters signify amino acids participating in HindIII 
digestion.  3 Residues 25-75 of SDF-1alpha are represented by a short dotted line.  Their amino acid sequence appears in the SDF-1α 
Insert entry.
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3240, and either 40 μg of each SDF-1a/RBS envelope plasmid as in the final production 
or 20 μg as in all preceding productions.  Wild type (WT) MoMLV was produced using 
25 μg of plasmid 3240 and 20 μg of the wild type envelope protein encoding plasmid, 
3245, throughout all experiments.  In experiments where different media are used during 
virus production, transfections were performed in DMEM supplemented with 8% FBS.  
Twenty-four hours post-transfection, producer cells were fed with the appropriate media 
variation and virus was harvested 24 hours later.  After each harvest, cells were fed with 
the next appropriate media variation and virus was harvested after 24 hours. 
 
 
SDS-PAGE and Western Blot Analysis.  Viral pellets and producer cell lysates were 
collected as described in Chapter 2.  Proteins were separated on an 8% SDS-PAGE gel, 
transferred to nitrocellulose, detected, and developed as described in Chapter 2.   
 
 
Results 
 
 
Design of SDF-1α Constructs.  Due to the difference in size between the fourteen amino 
acid Sst and that of SDF-1α, a slightly modified design concept based on the Sst/RBS 
chimera was applied.  Using structural representations of FrMLV and SDF-1α (PDB 
accession number 1VMC) [68] we used the Swiss-Model [69] and RasMol [70, 71] 
protein modeling programs in an attempt to position SDF-1α in such a way as to replace 
the endogenous receptor binding site and have the least amount of impact on the natural 
structure of MoMLV envelope, thus maintaining proper folding and function of the 
envelope protein.   
 
 This modeling indicated that the least obtrusive way to incorporate SDF-1α in place 
of the putative RBS would be to replace the segment of SU beginning at amino acids at 
leucine 58 (L58) or tyrosine 60 (Y60) and ending at leucine 89 (L89) or glutamic acid 87 
(E87).  Previous studies had shown that the C-terminal end of SDF-1α has little to no 
bearing on its ability to bind to or activate the CXCR-4 receptor [68, 72], therefore we 
were comfortable experimenting with varying lengths of SDF-1α in the hope that slightly 
reducing its size might be more conducive to proper folding.   
 
 We also wanted to determine if the addition of flexible linkers preceding SDF-1α 
would help preserve its natural structure and activity within the context of the MoMLV 
envelope as well as that of the envelope itself.  Serine-glycine linkers were introduced in 
two different locations, the first location being directly upstream of the MoMLV/SDF-1α 
junction and the second slightly more upstream at histidine 50 (H50).  Two different 
forms of the linker, each potentially offering slightly different levels of flexibility, were 
also introduced at the origin of the junction between these two proteins. 
 
 As a positive control, the SDF-1α/RBS-G chimera containing an insertion of the 
SDF-1α amino acids 22 through 89 at MoMLV residue 79 was generated as previously 
described [54].  This construct was reported to have maintained the ability to infect cells 
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expressing the ecotropic MLV receptor as effectively as the wild type MoMLV and to 
have gained the ability to infect cells expressing the CXCR-4 receptor [54].   
 
 
The Chimeric SDF-1α/RBS Proteins Were Not Expressed Well on Viral Particles.  
Initial attempts to produce virions expressing the SDF-1α/RBS envelope resulted in very 
low envelope expression.  To combat potential folding issues we took two different 
approaches.  First, in the event that SDF-1α folding might require a less acidic 
environment, we produced virus in BES-buffered DMEM (pH 7.2).  Secondly, to correct 
misfolding due to the misplacement of cystine bonds, we added a low level (1 μg/L) of β-
mercaptoethanol (2-mercaptoethanol, Sigma; β-Me) to the producer cell media 
duringvirus production.  Neither method produced chimeras with levels of SU 
comparable to MoMLV.  In fact, β-Me demonstrated the ability to reduce more than just 
disulfide bonds by diminishing MoMLV envelope expression as well (Figure 3-1).  There 
was no producer cell death associated with either method. 
 
 
SDF-1α/RBS Virus Did Not Effectively Transduce 293 Cells Transiently Expressing 
CXCR-4.  Neither virions produced in untreated DMEM nor those produced in BES-
buffered DMEM demonstrated the ability to infect cells expressing CXCR-4 (Figure 3-2).  
Western blot analysis of the virions (Figure 3-3) revealed an enhanced accumulation of 
the precursor envelope protein (gp75) which consisted of uncleaved SU and TM.  This 
phenomenon has been seen in both infectious and noninfectious virus in the past and has 
no bearing on whether or not virions are able to transduce their genetic material [33].  An 
accumulation of precursor in this case correlated with a slightly increased ability to 
transduce NIH 3T3 cells which is an undesirable trait in a vector designed for mouse 
studies.   
 
 In an effort to increase expression of mature chimeric SU, we doubled the mass of 
envelope plasmid used in transfecting the H1-BAG producer cells.  These chimeric 
viruses also showed a negligibly low level of transduction on 293/CXCR4 cells while 
continuing to demonstrate the ability to transduce NIH 3T3 cells (Figure 3-4) even 
though the level of chimeric SU on these virions was slightly increased (Figure 3-5).  
Analysis of the cell lysates (Figure 3-5) indicated that there may be a cleavage defect as 
evidenced by the lack of cleaved SU present in A, B, D, and E.  The C and G envelopes 
appeared more amenable to cleavage by the host cell furin-like protease. 
 
 
Discussion 
 
 Together these results suggest that the sheer size of SDF-1α restricts its usefulness in 
this particular design.  However, we believe there are other factors beyond size involved 
that may bear further experimentation.  Our constructs incorporated residues K22 through 
K89. The SDF-1α binding site has been determined to encompass N-terminal residues 1 
through 9 [72] while activation of the CXCR-4 receptor required amino acids 1-17 [68].  
An SDF-1α/RBS chimera in which this smaller fragment of the ligand is substituted for 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1.  Western Blot Analysis of Viral Pellets Produced in BES-buffered 
DMEM and β-Me DMEM.  SDF-1α/RBS viruses A through G and wild type (WT) 
MoMLV were produced in BES-buffered media (top) or media containing β-
mercaptoethanol [1 μg/L] (bottom).  The viral supernatant was pelleted and analyzed by 
SDS-PAGE and Western blot using antibody to the surface (gp70) protein of MoMLV 
envelope. Antibody to MoMLV capsid (p30) was used as a loading control. 
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Figure 3-2.  SDF-1α/RBS Infection in Unaltered DMEM and BES-buffered DMEM.   
(A) The level of CXCR-4 expressed on the surface of the 293 cells was quantified using 
flow cytometry the same day as the cells were exposed to the viral supernatants.  (B) NIH 
3T3 cells, 293 cells, and 293 cells transiently expressing the CXCR-4 receptor were 
exposed to viral supernatants and the resulting infection was quantitated by end-point 
dilution (WT MoMLV and SDF-1α/RBS G) or by counting individual cells (SDF-
1α/RBS B through E) transduced with the lacZ gene.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-3.  Western Blot Analysis of Viral Pellets Produced in DMEM and BES-
buffered DMEM.  SDF-1α/RBS viruses A through G and WT MoMLV were produced 
in unaltered DMEM (top) or BES-buffered DMEM (bottom).  The viral supernatant was 
pelleted and analyzed by SDS-PAGE and Western blot using antibody to the surface 
(gp70) protein of MoMLV envelope.  Antibody to MoMLV capsid (p30) was used as a 
loading control. 
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Figure 3-4.  Double Envelope SDF-1α/RBS Infection in DMEM.  (A) The level of 
CXCR-4 expressed on the surface of the 293 cells was quantified by flow cytometry the 
same day as the cells were exposed to the viral supernatants.  (B) NIH 3T3 cells, 293 
cells, and 293 cells transiently expressing the CXCR-4 receptor were exposed to viral 
supernatant and the resulting infection was quantitated by end-point dilution (WT 
MoMLV and SDF-1α/RBS G) or by counting individual cells (SDF-1α/RBS B through 
E) transduced with the lacZ gene.                            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-5.  Effect of Doubling the SDF-1α/RBD Plasmid Mass during Virus 
Production.  48 hour viral supernatant (top) was pelleted and analyzed by SDS-PAGE 
and Western blot using antibody to the surface (gp70) protein of MoMLV envelope.  An 
antibody to MoMLV capsid (p30) was used as a loading control.  Producer cell lysates 
(bottom) were harvested once virus production was complete and analyzed by SDS-
PAGE and Western blot using antibody to the surface (gp70) protein of MoMLV 
envelope. Antibody to actin (p42) was used as a loading control. 
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the putative RBS may allow for better retention of the MoMLV envelope structure and 
promote higher levels of expression.  The positive control SDF-1α insertion construct, 
SDF-1α/RBS G, gave a very low but consistent level of infection.  Restrictions placed on 
the SDF-1α conformation by the lack of flexibility inherent in its design may have forced 
the accessibility of a low affinity binding site within this portion of SDF-1α that allowed 
entry via the CXCR-4 receptor.   
 
 As discussed in Appendix B, the configuration of the replacement peptide and the 
location of its binding site relative to the envelope protein may also be a limitation.  If 
this is the case, these smaller SDF-1α/RBS chimeras may express chimeric envelope 
proteins comparable to that of wild type virus while remaining unable to infect cells 
expressing CXCR-4.  In this instance, perhaps the portion of CXCR-4 tropic HIV-1 SU 
protein, gp120, which is responsible for binding this receptor would be amenable to use 
in this design.  Unfortunately, the exact sequence that binds the co-receptors including 
CXCR-4 remains unknown, although versions of the V3 loop within gp120 have 
demonstrated the ability to interfere with anti-CXCR-4 antibody binding suggesting that 
this loop may be involved in the interaction [73].   
 
 A lingering concern is the ability of these chimeras to infect NIH 3T3 cells.  The 
amino acids responsible for ecotropic receptor binding had been replaced by SDF-1α.  
Particles in which MoMLV residues 72-85 were deleted (del RBS) demonstrated no such 
ability.  A very low level of infection by the Sst/RBS chimera was also observed on NIH 
3T3 cells [46].  Perhaps these chimeras are able to infect via unidentified receptors on 
these cells able to bind the Sst and SDF-1α ligands.  Another possibility would be that 
these human ligands possess the ability to cross react with murine CXCR-4 and Sst 
receptors.  However, NIH 3T3 cells are not known to express CXCR-4 [74] or SstR1-5 
[75, 76].
24 
Chapter 4.  Mutational Analysis of the MoMLV Heparin Binding Site 
 
 
Introduction 
 
 Heparin and heparan sulfate are both members of the glycosaminoglycan (GAG) 
family differing in their pattern of sulfation which affects the ligands with which they 
interact.  Heparan sulfate occurs naturally on mammalian cell plasma membranes as a 
post-translational modification of certain families of membrane proteins referred to as 
heparan sulfate proteoglycans (HSPG).  Many proteins are known to bind HSPG through 
the use of common consensus heparan binding site (HBS) sequences defined as 
XBBBXXBX or XBBXBX where X is any amino acid and B is any basic amino acid 
(lysine, arginine, or histidine) [77, 78].   
 
 Several viruses have been shown to use varying degrees of HPSG binding as a means 
of initial attachment to their host cell.  Examples include enveloped viruses, such as the 
herpesviruses (HSV, HHV, and CMV) [79-81], respiratory syncytial virus (RSV) [82], 
HIV-1 [83, 84], MMTV [85], and MLV (FrMLV and Amphotrophic MLV) [86, 87], as 
well as several nonenveloped viruses such as adenovirus type 2 and 5 (AdV-2 and -5) 
[88], adeno-associated virus type 2 (AAV-2) [89], and foot-and-mouth disease virus 
(FMDV) [90].  Although several methods were used to determine the ability of these 
viruses to bind heparan sulfate, the two most informative experiments remained to be 
exposure of the viral supernatant to soluble heparan sulfate or pretreatment of host cells 
with heparanase prior to infection.  Additionally, the MMTV study incorporated a 
mutated envelope protein (del HBS) which confirmed the reduction in infection shown 
during the heparan sulfate precompetition assay.  These studies collectively identified a 
wide range of viruses which rely on their capacity to bind cell surface HSPG to 
effectively infect their host cells. 
 
 A neuropathogenic variant of the Friend MLV (FrMLV), PVC-211, was recognized 
after passage of FrMLV in rats [91].  Further characterization of this virus demonstrated 
that the use of the ATRC-1 receptor was conserved, but the host cell preference of PVC-
211 had been shifted to brain capillary endothelial cells (BCEC) thus allowing the virus 
to penetrate the blood-brain barrier [92, 93].  Comparison to wild type FrMLV revealed 
two point mutations within the RBD, glutamic acid 116 to glycine (E116G) and glutamic 
acid 127 to lysine (E127K), which were shown to be responsible for this expanded tropism 
[94, 95].  The E127K mutation conferred an additional heparin binding motif overlapping 
the one naturally found in VRC [86].  It has been suggested that this acquisition increased 
the naturally low affinity of FrMLV for heparan thus enhancing attachment and allowing 
PVC-211 to infect ECC more efficiently than FrMLV [86].  Based on the sequence 
homology of MoMLV and FrMLV, we proposed that the addition of an overlapping HBS 
could also increase MoMLV infection.   
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Materials and Methods 
 
 
Construction of Heparin Binding Site Mutant Plasmids.  Several different approaches 
were necessary to introduce all the desired mutations.  Mutagenic oligonucleotides used 
to construct the HBS mutants and those specifically created for this project are listed in 
Table 4-1.  Table 4-2 lists the PCR parameters used to create each construct. 
 
 
 Envelope Only Constructs.  Since the gag-pol-env encoding plasmid 752 is too large 
for use as the template for in vitro mutagenesis using PCR methods, the env encoding 
plasmid TS45 (described in Chapter 2) was used as the template. Using the modified 
ExSite mutagenesis protocol described in Chapter 2, oligonucleotide primers were 
annealed to plasmid TS45 template DNA and individual products of the mutagenesis 
were recovered after introduction into E. coli DH5-α.  Sequence analysis of the purified 
plasmid DNAs indicated that the mutated sequence had not completely been introduced 
during this initial process.  This partial transfer of the desired nucleotide changes from 
the mutagenic oligonucleotide primers resulted in missing nucleotides. We attempted to 
fill these gaps in sequence using Klenow(exo+) (New England Biolabs).  This method was 
successful in obtaining only one of the desired mutants, TS45/HBS-4.  Two approaches 
were taken to obtain the remaining mutants.  First, QuikChange mutagenesis (described 
in Chapter 2) was used to introduce the missing nucleotides into those plasmids with one 
or two base pairs missing in the codon for histidine 110 (H110) (numbering relative to 
MoMLV envelope N-terminus); TS45/HBS-1B, 2B, and 7B were obtained using this 
method.   Next, QuikChange mutagenesis was used to mutate TS45/HBS-1B into 
TS45/HBS-3B.  Finally, we employed the use of ExSite mutagenesis to introduce the 
TS45/HBS-5B, 6B, and 8 mutations to the TS45/HBS-4 plasmid.   
 
 
 Gag-pol-env Constructs.  In light of the negative RCR assay results for virus 
produced using the two plasmid system and the nature of the DNA required for use of the 
three plasmid system (see Chapter 2), we opted to produce virus using the two plasmid 
system.  To facilitate the use of this system, a PCR amplified portion of DNA containing 
each of the mutated HBS sequences was subcloned from the TS45 plasmid background 
using the PmlI and BspEI restriction sites into GV752 plasmid DNA (described in 
Appendix A).   
 
 
 Del RBS Gag-pol-env Constructs.  The portion of the TS45 plasmid and each 
TS45/HBS plasmid spanning glutamic acid 86 (E86) to the BspEI site was amplified.  
During this amplification, the bases encoding the RBS (amino acids 72 - 85) were 
replaced with a nine nucleotide sequence encoding the amino acid sequence YAS and 
containing a unique MluI restriction enzyme site. (see Table 4-1 for complete sequence of 
oligonucleotides).  We then digested the product with MluI and BspEI and subcloned it 
into the GV752 plasmid.   
 
Table 4-1.  Table of Oligonucleotides Used in the Production of HBS Mutation Constructs 1 through 8. 
 
Name Sequence 
HBS Mut 1 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctcatagaccgagaaagagtaagagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 2 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctcatagaccgagacgtagtaagagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 3 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctcatagaccgagacatagtaagagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 4 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctaagaagccgaagaagagtaagagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 5 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctagaagaccgagacgtagtagaagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 6 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctcatagaccgagacatagtcgtagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut 7 Fwd 5’- caagagtaacgaaggcttctacgtgtgtcctggtcctcataagccgaagcatagtaagagctgcggtggaccggactccttctactgtgcctattg -3’ 
HBS Mut Rev 5’- tgagttgtctggtctagcttgag -3’ 
HBS Mut 1B Fwd 5’- caagctagaccagacaactcacaagagtaacgaaggcttc -3’ 
HBS Mut 1B Rev 5’- gaagccttcgttactcttgtgagttgtctggtctagcttg -3’ 
HBS Mut 2B Fwd 5’- caagctagaccagacaactcacaagagtaacgaaggcttctac -3’  (HPLC purified) 
HBS Mut 2B Rev 5’- gtagaagccttcgttactcttgtgagttgtctggtctagcttg -3’        (HPLC purified) 
HBS Mut 3B Fwd 5’- ctggtcctcatagaccgagacatagtaagagctgcggtggac -3’ 
HBS Mut 3B Rev 5’- gtccaccgcagctcttactatgtctcggtctatgaggaccag -3’ 
HBS Mut 5B Fwd 5’- cgtcgtcctcgtcgttcgcgaagctgcggtggaccggactc -3’ 
HBS Mut 6B Fwd 5’- catcgtcctcgtcattcgcgaagctgcggtggaccggactc -3’ 
HBS Mut 7B Fwd 5’- ctcaagctagaccagacaactcacaagagtaacgaaggcttctac -3’ 
HBS Mut 7B Rev 5’- gtagaagccttcgttactcttgtgagttgtctggtctagcttgag -3’ 
HBS Mut 8 Fwd 5’- gctgcacctgcagcaagcgctagctgcggtggaccggactc -3’ 
HBS Mut B Rev 5’- aggaccaggacacacgtagaag -3’ 
del RBS Fwd 5’- atataaacgcgtccgaagaacctttaacctccctcac -3’ 
del RBS Rev 5’- cctgatgtgttttgggaactgc -3’ 
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Table 4-2.  PCR Mutagenesis Parameters Used to Create SDF-1α Vectors and Amplify the SDF-1α Insert. 
 
Product Name Parameters 
TS45/HBS-1 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min.; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-1B 1 cycle: 95 °C for 30 sec.; 25 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-2 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min.; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-2B 1 cycle: 95 °C for 30 sec.; 25 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-3B 1 cycle: 95 °C for 30 sec.; 25 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-4 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min.; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-5B 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min; 4 °C hold 
TS45/HBS-6B 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min; 4 °C hold 
TS45/HBS-7 1 cycle: 95 °C for 2 min.; 5 cycles: 95 °C for 30 sec., 54 °C for 1 min., 68 °C for 10 min.; 
25 cycles: 95 °C for 30 sec., 59 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-7B 1 cycle: 95 °C for 30 sec.; 25 cycles: 95 °C for 30 sec., 55 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
TS45/HBS-8 1 cycle: 95 °C for 2 min.; 25 cycles: 95 °C for 30 sec., 63 °C for 1 min., 68 °C for 10 min.; 4 °C hold 
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Cell Lines, Virus Production, Infection, and Titration.  H1-BAG cells were used for 
virus production using the two plasmid system described in Chapter 2.  NIH 3T3 cells 
were used to titer all virus as described in Chapter 2.  In addition to the X-gal stain, one 
well of infected NIH 3T3 cells in each set of 4 per virus was stained with basic fuchsin 
(Sigma), a positively charged dye that binds to negatively charged molecules, primarily  
the nucleic acid in the nucleus of cells. 
 
 
SDS-PAGE and Western Blot Analysis.  Viral pellets and producer cell lysates were 
collected as described in Chapter 2.  Viral pellets were separated on a 10-20% gradient 
SDS-PAGE gel and cell lysates were separated using an 8% SDS-PAGE gel as described 
in Chapter 2.  The separated proteins were transferred to nitrocellulose, detected, and 
developed as described in Chapter 2. 
 
 
Results 
 
 
Design of HBS Constructs.  Table 4-3 shows an alignment of the protein sequences of 
the MLV heparin binding sites in MoMLV, FrMLV, and all HBS mutants.  The FrMLV 
envelope has a shift of two amino acids in numbering when compared to that of MoMLV.  
HBS-1 is a recapitulation of the PVC-211 E127K mutation and HBS-2 and -3 are 
variations on that theme using the remaining two basic amino acids, arginine and 
histidine.  The HBS mutations 4 and 5 change all the basic amino acids in the 
overlapping motifs to lysine and arginine respectively.  Since a cluster of histidines may 
be incompatible with maintaining the alpha-helical structure of the HBS and might cause 
misfolding, the HBS-6 and -7 mutations consist of histine-arginine and histidine-lysine 
combinations.  The final mutation, HBS-8, incorporates the neutral amino acid alanine in 
place of all basic amino acids in both heparin binding motifs.   
 
 Fusion assay results (see Appendix B) indicated that virions expressing the del RBS 
envelope (see Chapter 3 for description) had the potential to infect at very low levels.  In 
brief, a version of α-complementation of the E. coli β-gal protein previously modified for 
use in mammalian cells [96-98] was employed to identify fusion occurring between cells 
expressing a particular receptor and cells expressing an envelope protein with the R-
peptide removed.  Removal of the R-peptide enabled the envelope protein to initiate 
fusion and allowed mixing of cytoplasm.  Once the cell contents were combined, proper 
folding of the β-gal protein required to process X-gal could be achieved by combination 
of the alpha and omega proteins expressed in each cell type [99, 100].  It was our 
thinking that any improvement of the heparin binding site should serve to increase this 
level of infection thus, we incorporated each of the afore mentioned HBS mutations into 
a del RBS background in addition to examining them in a wild type envelope 
background..   
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Table 4-3.  Alignment of the Amino Acid Sequence of the Putative Heparin Binding Sites in Wild Type and Mutant Envelope 
Proteins. 
 
Name Sequence 
MoMLV HBS C119PGP1HRPRESKSCGGP134 
FrMLV HBS C121PGSHRPREAKSCGGP136 
PVC-211 HBS C121PGSHRPRKAKSCGGP136 
HBS Motif 1             XBBXBX 
HBS Motif 2                     XBBXBX 
Mutant HBS Motif             XBBXBBXBX 
HBS 1 (E127K) C119PGSHRPRK2SKSCGGP134 
HBS 2 (E127R) C119PGSHRPRRSKSCGGP134 
HBS 3 (E127H) C119PGSHRPRHSKSCGGP134 
HBS 4 (all B=K) C119PGPKKPKKSKSCGGP134 
HBS 5 (all B=R) C119PGPRRPRRSRSCGGP134 
HBS 6 (all B=RorH) C119PGPHRPRHSRSCGGP134 
HBS 7 (all B=KorH) C119PGPHKPKHSKSCGGP134 
HBS 8 (all B=A) C119PGPAAPAESASCGGP134 
 
1Heparin binding motifs are indicated in boldface type.  2Amino acids altered as a result of nucleotide mutagenesis are enlarged, 
italicized, and shaded gray.
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HBS Mutations 4, 5, 7, and 8 Impede MoMLV Envelope Cleavage.  HBS mutants 1, 2, 
3, and 6 expressed levels of SU (Figure 4-1) and gave infection (Figure 4-2) comparable 
to that of wild type MoMLV.  These same variations when coupled with the del RBS 
mutation, retained their ability to express and process SU but could no longer infect NIH 
3T3 cells (Figure 4-2).  HBS mutations 4, 5, 7, and 8 did not assemble their SU onto 
virions (Figure 4-1) which would be an evident reason for their failure to give infection 
(Figure 4-2).  Analysis of producer cell lysates (Figure 4-1) indicated that, while the 
SU/TM precursor was expressed, it was not able to be cleaved.  The data did not 
determine if the processing failure was due to a block in transiting the Golgi or 
sequestration of the cleavage site due to misfolding.   
 
 
HBS Mutant Envelope Proteins 1, 2, 3, and 6 Influence Syncytia Phenotype.  While the 
overall number of syncytia was not increased, the phenotype of syncytia formed by cells 
infected with wild type RBS/HBS mutants 1, 2, 3, and 6 differed from those formed 
during a wild type infection (Figure 4-3).  Upon gross examination of micrographs, there 
appeared to be fewer cells involved in syncytia formed during wild type MoMLV 
infection when compared to those formed by cells infected with HBS-1, -2, -3, or -6.  
Additionally, there was an apparent decrease in the level of β-gal activity within those 
syncytia formed by the HBS mutant viruses.  These results were not observed on cells 
infected with the del RBS/HBS-1, -2, -3, or -6 mutants. 
 
 
Discussion 
 
 Wild type RBS and del RBS HBS mutants 4, 5, 7, and 8 were unable to cleave the 
precursor SU into its mature form.  These mutants share mutations with accumulations of 
a basic amino acid, each of which differ in their level of steric hindrance.  The net level 
of positive charge would have remained similar throughout all the HBS mutants, 
suggesting that other considerations caused the defect in precursor processing.  Since this 
unexpected outcome occurred regardless of which basic residue was repeated in the 
motif, it appeared that the length and flexibility of the side chains in the repetitive motifs 
was not responsible for the defect.  Alanine, although neutral, is a hydrophobic amino 
acid which, when asked to be present in a run, may have been prone to bury itself within 
the envelope structure rather than achieving the proper conformation.   An exception to 
this correlation between the runs of the same amino acid and cleavage defect is HBS-7.  
This mutant contained a combination of charges within its HBS.  The less bulky and 
more flexible side chain of lysine replaced arginine at positions 124 and 126 (R124K and 
R126K) and the aromatic histidine replaced glutamic acid at position 127 (E127H).  The 
E127H mutation was tolerated in HBS-3, but its combination with the R to K mutations 
appears unfavorable.  Previous studies have shown that neither histidine nor long 
stretches of one basic amino acid are commonly incorporated in heparan binding motifs 
and that histidine in general poorly binds HSPG [101, 102].   
 
  The altered syncytia phenotype observed on cells infected with virions expressing 
wild type RBS and mutant HBS 1, 2, 3, or 6 may indicate that, once these virions bound 
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A.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1.  Western Blot Analysis of HBS Mutant Proteins.  (A) Viral supernatant 
was pelleted and analyzed by SDS-PAGE and Western blot using antibody to the surface 
(gp70) protein of MoMLV envelope.  Antibody to MoMLV capsid (p30) was used as a 
loading control.  (B) Producer cell lysates were harvested once virus production was 
complete and analyzed by SDS-PAGE and Western blot using antibody to the surface 
(gp70) protein of MoMLV envelope.  Antibody to actin (p42) was used as a loading 
control.
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Figure 4-2.  HBS Mutant Infection.  NIH 3T3 cells were exposed to viral supernatant and infection was quantified by end-point 
dilution.  The values of GV752, HBS-1, HBS-2, HBS-3, and HBS-6 are the average of results from 2 independent experiments 
normalized by their positive control (GV752) values.  Experiment 1 values were: 6 x 105, 4 x 105, 6 x 104, 8 x 105, and 8x105.  
Experiment 2 values were: 6 x 105, 9 x 105, 3 x 104, 3 x 104, and 1 x 105.
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Figure 4-3.  HBS Mutant Syncytia.  (A) Infected NIH 3T3 cells described in Figure 4-2, 
after having been fixed and stained for β-gal activity, were stained with basic fuchsin to 
further define cell nuclei.  (B) Syncytia within ten contiguous fields captured using a 
Zeiss Axioplan2 epifluorescent microscope were counted and reported as individual 
units.  One syncytia was defined as any cell with three or more nuclei within its plasma 
membrane.
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their receptor, they were able to induce fusion more swiftly and efficiently than those 
expressing the wild type protein. It is also possible that these HBS mutations increased 
heparan binding affinity to such an extent that a fusion “bridge” was permitted to form 
between several cells.  A combination of these two possibilities may be the most likely 
explanation for this phenomenon.  The available β-gal in the syncytia formed by these 
mutant virions may simply have been too dilute to be observed.   
 
 Human breast cancer cells have been shown to overexpress HSPG [103-106].  Based 
on this observation, an oncolytic, conditionally replicating adenoviral (CRAd) vector was 
recently developed and has been shown to be effective when delivered either 
intratumorally or intravenously [107].  HBS mutant viruses 1, 2, 3, and 6 may offer an 
increased preference for breast cancer cell and one or more of these mutated heparan 
binding sites may favor one cell type over another based on interactions between heparin 
versus heparan sulfates or other subtle differences within the heparan sulfates expressed 
on breast cancer cells.  Breast cancer cell lines should be transiently transfected with 
DNA encoding for the ATRC-1 receptor and then exposed to wild type and HBS mutant 
virus.  If heparin binding is indeed a useful indirect targeting method, the HBS mutant 
virus should infect at higher titers than wild type MoMLV.   
 
 In addition to infection data, virus binding assays should be performed on wild type 
and del RBS HBS mutants as well as wild type MoMLV to quantitate the level of virus 
binding to NIH 3T3 cells and those breast cancer cell types that were infected by the wild 
type RBS HBS mutants both expressing and not expressing the ecotropic receptor.  
Briefly, cells would be exposed to virus and fixed in suspension.  Then goat anti-
Rauscher-gp70 (Quality Biotech, Inc.) antibody would be incubated with the fixed 
cell/virion complexes followed by donkey anti-goat antibody conjugated to 
Phycoerythrin (PE) (Jackson Laboratories, Inc.) and analyzed by flow cytometry.  This 
assay would confirm infection data as well as demonstrate (through the del RBS HBS 
mutants and interactions with breast cancer cells not expressing ATRC-1) a receptor 
independent reaction and indicate small differences between each mutant. 
 
 The variations within these mutants may have pH advantages over each other.  For 
example, the HBS-3 and -6 mutations may impart a low pH preference based on the 
lower pKa of the histidine (pKa of 6.1) at position 127 as compared to lysine (pKa of 
10.5) or arginine (pKa of 12.5).  This could be examined by lowering the pH during 
infection of breast cancer cell lines or NIH 3T3.  These results would be best visualized 
by using the virus binding assay described above as the differences are likely to be 
minute.  Since the tumor microenvironment tends to be one of acidic pH [108], HBS 
mutants 3 and 6 may more effectively infect within the tumor than HBS mutants 1 or 2. 
 
 Prior to performance of these future studies, the NIH 3T3 cell line and a panel of 
breast cancer cell lines will need their levels of heparan sulfate expression quantified.  
The most straightforward way to accomplish this is by flow cytometry using an antibody 
to HSPG.  In addition, the most effective method of transfection for each breast cancer 
cell line will need to be determined as was done for the MDA-MB-231 cell line in 
Appendix B.  Finally, the wild type RBS and del RBS HBS mutants 1, 2, 3, and 6 will 
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need to be analyzed to determine their ability to bind soluble heparan sulfate as described 
by Zhang, et. al. [85] since the del RBS constructs were unable to indicate any 
improvement in infection.   
 
 Finally, these mutant viruses should be examined in vivo.  Recall that these HBS 
mutants contain the natural MoMLV RBS and that the PVC-211 FrMLV variant had 
extended its tropism to include BCEC [92].  This ability allowed the virus to cross the 
blood-brain barrier, but did not confer the ability to infect neurons or astroglia despite the 
presence of lesions in the central nervous system and subsequent neurodegenerative 
disease [91, 92].  A comparison of wild type MoMLV with HBS mutants 1, 2, 3, and 6 in 
neonatal rats as was done for PVC-211 and FrMLV would be an effective way to 
determine if these HBS mutants also have the ability to cross the blood-brain barrier and 
cause neurodegenerative disease.  Mutants that lack the ability to cross the blood-brain 
barrier yet exhibited an enhanced affinity for HSPGs would be likely candidates for 
breast cancer cell targeted vectors.  Those able to enter the brain might be uniquely 
qualified to target cancer cells in that area.  
Chapter 5.  Discussion 
 
 
 Targeting one specific cell type within the context of the human body is a daunting 
task.  Many attempts have been made to accomplish this important goal, all with limited 
or no success.  The Sst/RBS chimera showed specificity for cells expressing Sst receptors 
in vitro, but will face a wider range of target cells in vivo.  Humans have five genes 
encoding receptors with similar Sst binding affinity but different cell-signaling properties 
which are upregulated on certain cancer cells.  These receptors are also expressed on 
pancreatic β-islet cells [109] as well as in the brain and numerous other tissues [110].  
Similarly, CXCR-4, the receptor for SDF-1α, is overexpressed on some breast cancer cell 
types as well being naturally expressed on immune cells and in the brain [111].  These 
superfluous targets would be encountered by suicide gene therapy vectors, infected, and 
eliminated just as innocent bystander cells are during chemotherapy and radiation 
treatment.   
 
 Since a receptor candidate that is expressed exclusively on tumor cells will be a rare 
find, it is likely that multiple layers of targeting will be necessary to reduce the ability of 
these vectors to deliver their cargo to normal cells.  In addition to the concepts of 
replacing the MoMLV RBS with a short ligand and manipulating the HBS, the PRR has 
demonstrated the ability to accept large insertions without interfering with envelope 
expression and assembly onto virions [21, 23, 31].  Ligands inserted into the PRR retain 
their ability to bind their receptor but are unable to induce all of the conformational 
changes necessary to mediate fusion of the viral envelope and the target cell membrane 
[31].  The combination of all three of these concepts into a single modified envelope 
protein might allow for a more cancer cell specific vector. 
 
 The epidermal growth factor (EGF) receptors (ErbB1 through 4) and SstR1 through 5 
colocalize on several breast cancer cell lines [112].  Expanding on the Sst/RBS design by 
inserting the fifty-three amino acid EGF sequence into the PRR may increase the 
probability that cells expressing both these receptors would be infected rather than cells 
expressing SstR only.  It should be noted, however, that Sst analogs have undergone 
clinical trials and demonstrated antiproliferative effects in breast cancer with limited side 
effects [113].  Additionally, clinical trials using cytotoxic analogs of Sst, bombesin, and 
luteinizing hormone-releasing hormone (LH-RH) were pending as of 2004 [114].   
 
 Another intriguing target for these retroviral vectors may prove to be cancer stem 
cells.  It has been shown that certain brain, blood, and breast tumors are initiated and 
maintained by mutated progenitor cells [115-119] which are resistant to 
chemotherapeutic treatment [120].  These cells, in mice, have been associated with and 
identified by the expression of CD44(+), CD24(-/low), and ESA(+) (epithelial-specific 
antigen) on their surface [116].  Unfortunately, these particular antigens would make poor 
targets in vivo.  For example, CD44 is expressed on most nucleated murine cells [121-
125] while CD24 is a common marker for the identification of immature cells of 
hematopoietic lineage and developing neurons [126-128] among other types of cells.  The 
concept of repairing these defective cells ex vivo and returning them to their original 
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location, however, is not outside the realm of possibility.  The ligand for CD24 is P-
selectin [129], the mature form of which is made up of 119 amino acids [130].  This 
ligand would be best suited to insertion in the MoMLV PRR.  As for the RBS-replacing 
ligand, further characterization of these cells would need to be performed since the ligand 
for ESA is unknown and the expression of CD44 would likely be common to stem cells 
and their daughter cells.   
 
 Selection of the ligand used to replace the RBS remains an extremely difficult task.  
The identification of an effective high-throughput tool to screen potential ligands for 
tumor-specific binding capability would be extremely useful toward further development 
of this method of entry targeting.  For example, the soluble GFP-tagged RBD developed 
in the Sitbon lab [131] could be utilized to ascertain ligands which allow proper envelope 
conformation and binding.  Detection of GFP using flow cytometry and the gp-70 
antibody would indicate which ligand-modified RBDs bound a particular target cell 
providing a method to screen many different RBDs and cell types efficiently.  This 
process would be best orchestrated in two steps whereby ligand-modified RBDs would 
first be screened against a cell type known to express the target receptor (either 
transiently or stably) and those chimeric envelope proteins showing promise in this area 
would be screened against cancer cell lines and primary tumor cells.  Virus production 
would ultimately be required to determine the ability of these envelope chimeras to 
induce fusion and infect their target cell, but many possibilities and combinations could 
be eliminated prior to that step through the use of this type of assay.   
 
 One issue to consider while teasing out the useful chimeric RBDs is the possibility of 
cancer cells having one or more downstream blocks to retroviral infection.  This research 
group has seen evidence of this type of impediment when working with neuroblastoma 
cell lines (F. Li and L. Albritton, unpublished results).  Amphotrophic MLV (A-MLV) 
enters cells using the PiT-2 receptor, a sodium-dependent potassium transporter [132] 
which is known to be expressed on a variety of human cell types.  A-MLV produced 
using our β-gal reporter system could be used to screen cancer cell lines and primary 
tumor cells. Those tumor cells showing levels of infection comparable to human 293 cells 
by the A-MLV would be good candidates for target cells lacking downstream blocks to 
entry.  Any cell lines unable to be infected by A-MLV would need their level of PiT-2 
receptor expression evaluated by either flow cytometry or Western blot analysis before 
jumping to the downstream block conclusion.  Another, more reliable, indicator of a 
downstream block to infection would be an infection using MLV particles pseudotyped 
with the vesicular stomatitus virus G protein (VSV-G).  The VSV-G protein is known to 
mediate entry into an extremely broad range of cell types, therefore any lack of infection 
could more reasonably be contributed to a downstream block and no evaluation of 
receptor expression would be required.   
 
 It is incredibly time consuming to produce enough chimeric MoMLV-based retroviral 
vector to ensure infection of its target cells.  For example, unconcentrated Sst/RBS virus 
infected only approximately 50% of cells expressing high levels of SstR2 [46].  This 
same virus was also rendered non-infectious after storage at -80 °C.  To increase 
infection, a method of concentrating these chimeras without damaging them must be 
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developed.  Here is an area where enhancing the HBS might impart an advantage beyond 
targeting.  Past studies have shown that the heparin binding properties of recombinant 
adeno-associated virus (rAAV) [133] and MoMLV particles pseudotyped with the VSV-
G envelope protein are amenable to purification by affinity chromatography and 
infectious particles were recovered under mild elution conditions (neutral pH and 0.35 M 
NaCl) [134, 135].  This method would serve to decrease the number of purification steps 
required and increase yield thus reducing the amount of time and effort required to 
produce MoMLV-based vectors.   
 
 While retroviral vectors are unlikely to replace conventional cancer treatments, they 
could be useful as a means to ensure a more complete eradication of cancerous cells after 
treatment with chemotherapy or radiation. This might allow for a reduction in the amount 
of the conventional treatment necessary and improve the patient's quality of life by 
decreasing side effects.  Incidentally, the immune suppression commonly resulting from 
treatment with chemotherapy or radiation therapy would serve to enhance infection with 
retroviral vectors.  Retroviral vectors also have the potential to serve as effective 
diagnostic and prognostic tools. For example, better visualization of cancer cells might be 
accomplished through delivery of a luminescent expression gene for more exact removal 
and tumor load calculation. 
  
 In conclusion, the innovative design of Sst/RBS is a wonderful start down an arduous 
path of selecting ligands targeted to limited cell types and identifying those with the 
capacity to mediate virus attachment and entry.  Combining this design with additional 
ligands inserted in the PRR and an enhanced HBS may improve the likelihood of delivery 
of a gene of interest to its intended target cells and the enhanced HBS may improve the 
amount of virus available for delivery.  Both of these are steps in the right direction 
towards the development of an effective retroviral vector.   
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Appendix A.  Supplemental Plasmids 
 
 
GV-1 through 5.  Sst/RBS Stabilization 
 
 
Rationale.  These constructs are based on the Sst/RBS construct described in Chapter 1.  
Sst/RBS infected at levels only half as potent as wild type MoMLV.  Possible 
explanations for this are a defect in either fusion or envelope stability.  Previous studies 
in the Albritton lab have shown that the point mutations Q227R and D243Y can rescue 
mutants defective in fusion and stability.  Additionally, an R95D has been shown to 
improve upon stability.  The mechanism by which these point mutations restore fusion 
and stability is unknown.   
 
 
Method.  In order to keep with the lab’s preference of producing the MoMLV using the 
three-plasmid system (packaging sequence and lacZ gene within the H1-BAG cell 
genome, gag and pol genes on one plasmid, env gene on another plasmid) to reduce the 
probability of a recombination event which would produce replication competent virions, 
all constructs were made using plasmid 3245 as their backbone with each insert bringing 
in not only the point mutations, but the Sst/RBS envelope sequence as well.   
 
 To create the GV-1 and 2 plasmids, plasmid 3245 was digested with PmlI and BspEI 
as were plasmids FL-28 (Sst/RBS) and MS-10 (Sst/RBS + R95D).  The ~ 800 bp bands 
from FL-28 and MS-10 and the ~ 6600 bp band from the 3245 plasmid were purified and 
ligated together. 
 
 To create the GV-3, 4, and 5 plasmids, the GV-2, 838 (H8R + Q225R + D243Y), 
2027 (H8R + Q227R), and 2059 (D243Y) plasmids were digested with BspEI and EcoRI.  
The ~ 1300 bp bands from plasmids 838, 2027, and 2059 and the ~ 6100 bp band from 
plasmid GV-2 were purified and ligated together.  All plasmids were verified by DNA 
sequencing.  Construction notes and plasmid maps may be found in Appendix C. 
 
 
GV-6. Plasmid 3240 Envelope Gene Reduction. 
 
 
Rationale.  While verifying the sequence of every available tube labeled plasmid 3420 in 
an effort to identify mislabeled DNA, we determined that the current 3240 plasmid 
contained 736 bp (245 amino acids) of the envelope protein coding sequence.  Since the 
RBD is contained in the first 688 bp (229 amino acids), there exists the potential for any 
virus produced using this plasmid to be contaminated with free RBD.  Previous studies 
have shown that free RBD has the ability to enhance infection at low levels and interfere 
with infections at moderate to high levels and that it can also rescue virus rendered non-
infectious due to fusion defects [136].   The removal of this contaminant in virus 
performance was absolutely necessary, especially where targeted studies were concerned.  
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Another issue arose in the form of increased probability of a homologous recombination 
event between this structural plasmid and the provirus located within the pBAG plasmid 
in the H1-BAG cell genome. 
 
 
Method.  A 3240 plasmid (JF 3240) was digested with HpaI.  The ends were filled using 
Klenow and the resulting blunt ends were ligated.  Three correct clones were identified 
via the loss of the HpaI site and verified by DNA sequencing.  Construction notes and a 
plasmid map may be found in Appendix C. 
 
 
GVTS45 and GV752.  Removal of the MluI Site in the pcDNA3_delNeo Plasmid 
CMV Promoter Sequence 
 
 
Rationale.  As the HBS mutants were being made and I was entering more data into the 
Vector NTI ™ program, I realized that there was an MluI site in the pcDNA3_del Neo 
backbone of all of the viral expression plasmids.  This became an issue when it was 
necessary to digest the 752_del RBS plasmid with MluI and insert the PCR amplified and 
mutated HBS sequences with the del RBS (and the MluI site contained therein) attached 
to their 5’ end into it.  Removal of this MluI site was also necessary for the del RBS 
design to truly be the “plug and play” vector it was designed to be. 
 
 
Method.  Plasmids TS45 and 752 were digested with MluI, the ends were Klenow filled 
and the resulting blunt ends were ligated.  Upon screening, only the TS45 clones showed 
a loss of the MluI site.  One clone was verified by DNA sequencing and named GVTS45.  
Irregular filling caused the loss of a “g” at the ligation junction when compared to the 
expected sequence of “acgcgcgcgt”.  The verified sequence reads “acgccgcgt”. 
 
 The SnaBI/EcoRI fragment of plasmid GVTS45 was PCR amplified using 
oligonucleotide primers pCMVas and M-17+2.  This PCR product and the 752 plasmid 
were digested with SnaBI and EcoRI.  Mini-prepped plasmids were screened for loss of 
the MluI site.  Three correct clones were confirmed by DNA sequencing and purified 
from individual E. coli Top 10F′ colonies.  This prep of GV752 plasmid DNA was used 
to produce virus using the two-plasmid system. The titer of this GV752 MoMLV was 
compared to that of wild type MoMLV. Construction notes and plasmid maps may be 
found in Appendix C. 
 
 
Results.  GV752 MoMLV was more infectious than the wild type MoMLV as illustrated 
in Figure A-1.  While it is possible and even probable that the removal of this MluI site 
created an enhancer sequence within the CMV promoter (the MluI site was located at the 
5’ end of the promoter), the reason for increased virus production using GV752 MoMLV 
was not determined.  
 
 
 
 
 
 
 
 
 
 
A. 
 
 
 
 
 
 
 
 Mock GV752 752 
 
 
B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A-1.  752 vs. GV752.  (A) Micrograph image of Mock, 752, and GV752 virus 
transduction of NIH 3T3 cells and (B) Western blot analysis of viral pellets.
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Appendix B.  Fusion Assay 
 
 
Rationale 
 
 Following up on the Sst/RBS design, F. Li and B. Ryu worked together to create 
plasmid 752-based constructs with other short ligands, similar in size and differing in 
disulfide bond configuration compared to the natural RBS replacing the WT MoMLV 
RBS sequence in an attempt to answer the following questions: 
 
1.  Is size the only restriction? MoMLV RBS = 14 amino acids (aa), Sst = 14 aa, 
SDF-1a = 61, 63, & 68 aa. 
2.  Is structure the only restriction? MoMLV RBS = two disulfide bonds, Sst = 1 
disulfide bond, SDF-1a = 2 disulfide bonds and a very different secondary 
structure from that of MoMLV RBS. 
3.  Is binding site location a restriction?  MoMLV = D84 (on C-terminal side of 
RBS), Sst = aa’s looped out by disulfide bonds, SDF-1a = N-terminal and 
underside of antiparallel β-sheets. 
4.  Are size, structure, and binding site location all restrictive? 
5.  Are only structure and binding site location restrictive? 
6.  Are only size and binding site location restrictive? 
7.  Are only structure and size restrictive? 
 
 Through their notebooks and miscellaneous planning sheets, I ascertained that 
plasmids with gastrin, galanin, oxytocin, substance P, endothelin, neurotensin, bombesin 
(GRP), two versions of bombesin flanked with cystines, RGD-14, and RGD-14 flanked 
by cystines replacing the RBS were constructed using PCR mutagenesis on the pUC-Env 
plasmid and subcloned into plasmid 752 by F. Li and B. Ryu.  Virus production and 
analysis was inconclusive based on the data we could locate. 
 
 In an effort to create a high throughput screening assay for chimeric 
envelope/receptor interactions, we employed an alpha complementation assay that had 
been modified for use in a eukaryotic system.  Briefly, the N-terminal portion of the β-gal 
enzyme (alpha) is expressed in one cell while a version with deletions in the alpha region 
(omega) is expressed in another.  When the cells fuse, the alpha protein rescues the 
ability of the omega protein to form the tetrameric structure necessary for β-gal activity.  
Moosman & Rusconi developed a mammalian version which was adapted by N. Landau 
for use in protein/protein interactions and further expanded as a fusion analysis tool to 
study the interaction between a CXCR-4 specific HIV-1 glycoprotein and its receptor 
[97].   This assay would allow for screening of chimeric RBS envelopes at a lower 
biosafety level than would be necessary when the potential for producing replication 
competent human-directed virus exists.  RCR assays have since been performed on virus 
produced using the two-plasmid system and the probability of replication competent virus 
production has been shown to be of negligible concern.  An additional benefit to this 
assay is the ability to use smaller amounts of lower purity DNA than is required for virus 
production. 
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 To modify this assay for use in screening chimeric envelope proteins, we needed an 
envelope protein that would be active in the context of a cell membrane.  The R-peptide 
is responsible for maintaining a non-fusogenic envelope conformation until budding has 
occurred at which time the R-peptide is cleaved to allow fusion of the virion with the cell 
membrane.  R-less envelope proteins are truncated at the R-peptide cleavage point (V616) 
thus allowing fusion as soon as the envelope protein is expressed on the host cell surface.   
 
 
Method 
 
 After determining which of these ligands had receptors that were expressed on the 
MDA-MB-231 breast cancer cell line, I amplified the BstEII/BamHI fragments from the 
oxytocin, substance P, endothelin, neurotensin, bombesin (GRP), 2 versions of bombesin 
flanked with cystines, RGD-14 flanked by cystines, and RGD-14 RBS chimeras using 
PCR and the env-10 and M-6 oligonucleotides, digested the ~ 1300 bp products with 
BstEII and BamHI, and purified the ~600 bp band.  I then digested the TS45-R-less 
plasmids with BstEII and BamHI and purified the ~6000 bp band and ligated the two 
fragments together to form Ligand X/RBS-R-less plasmids. 
 
 The fusion assay was performed as follows: Transfect 293 cells with the alpha and R-
less envelope constructs.  Transfect MDA-MB-231 cells with the omega plasmid.  
Combine the two cell lines as desired at a 1:1 ratio and seed 24-well plates.  Forty-eight 
hours later, fix and stain the 24-well plates with X-gal and count the number of syncytia 
expressing β-gal activity. 
 
 Breast cancer cell lines are notoriously difficult to transfect.  To determine the best 
method, I tried three different reagents in many different combinations.  Trans-IT (Mirus) 
in DMEM was the most effective.  See Table B-1 for a complete list of conditions and 
results.   
 
 
Results 
 
 Unfortunately, low levels of fusion are nearly impossible to detect accurately using 
this assay (Figure B-1).  Even Sst/RBS Env partnered with SstR5, which infects in the 
105 range, failed to form detectable syncytia.  There was also a low level of individual 
cells expressing β-gal activity.  Additionally, the potential for false positives was 
indicated in the del RBS/EcoR combination.  Three syncytia were observed (in three 
wells with an average of one per well), but the del RBS virus did not infect NIH 3T3 cells 
at all (see Chapter 4). 
Table B-1.  Transfection Optimization. 
 
            Field 1 Field 2     
Date of 
Analysis Cell Line 
Ratio 
(Lipid:DNA) 
ug 
pGL Reagent 
% Confluent at 
Transfection 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
Average% Notes: 
2/15/2007 MDA-MB-231 3:1 5 FuGene6 60% 40 3 7.5% 30 4 13.3% 10.4% 
24 hours 
post-TF 
2/15/2007 MDA-MB-231 3:1 10 FuGene6 60% 43 5 11.6% 32 1 3.1% 7.4% 
24 hours 
post-TF 
2/15/2007 293 3:1 5 FuGene6 60% 103 23 22.3% 109 26 23.9% 23.1% 24 hours post-TF 
2/15/2007 293 3:1 10 FuGene6 60% 102 45 44.1% 78 29 37.2% 40.6% 24 hours post-TF 
2/15/2007 293 6:1 5 Lipofectamine 60% 45 28 62.2% 58 35 60.3% 61.3% 24 hours post-TF 
2/18/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 20 7 35.0% 18 5 27.8% 31.4% 
24 hours 
post-TF, no 
rinse before 
adding 
complex, 
fresh media 
after 4 hours 
2/19/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 19 9 47.4% 26 8 30.8% 39.1% 
48 hours 
post-TF, no 
rinse before 
adding 
complex, 
fresh media 
after 4 hours 
2/19/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 28 8 28.6% 17 9 52.9% 40.8% 
24 hours 
post-TF, split 
2x before TF, 
no rinse 
before adding 
complex, 
fresh media 
after 4 hours 
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Table B-1 (continued). 
 
            Field 1 Field 2     
Date of 
Analysis Cell Line 
Ratio 
(Lipid:DNA) 
ug 
pGL Reagent 
% Confluent at 
Transfection 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
Average% Notes: 
2/20/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 24 5 20.8% 25 6 24.0% 22.4% 
48 hours 
post-TF, split 
2x before TF, 
no rinse 
before adding 
complex, 
fresh media 
after 4 hours 
2/18/2007 293 6:1 5 Lipofectamine 60% 65 47 72.3% 37 30 81.1% 76.7% 
24 hours 
post-TF, no 
rinse before 
adding 
complex, 
fresh media 
after 4 hours 
2/19/2007 293 6:1 5 Lipofectamine 60% 135 63 46.7% 103 53 51.5% 49.1% 
48 hours 
post-TF, no 
rinse before 
adding 
complex, 
fresh media 
after 4 hours 
2/18/2007 293 6:1 5 Lipofectamine 60% 95 50 52.6% 88 47 53.4% 53.0% 
24 hours 
post-TF, no 
rinse before 
adding 
complex, 2x 
media after 4 
hours 
2/19/2007 293 6:1 5 Lipofectamine 60% 151 65 43.0% 94 42 44.7% 43.9% 
48 hours 
post-TF, no 
rinse before 
adding 
complex, 2x 
media after 4 
hours 
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Tab le B-1 (continued). 
 
            Field 1 Field 2     
Date of 
Analysis Cell Line 
Ratio 
(Lipid:DNA) 
ug 
pGL Reagent 
% Confluent at 
Transfection 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
Average% Notes: 
2/19/2007 293 6:1 5 Lipofectamine 60% 102 62 60.8% 89 51 57.3% 59.0% 
24 hours 
post-TF, split 
2x before TF, 
no rinse 
before adding 
complex, 
fresh media 
after 4 hours 
2/20/2007 293 6:1 5 Lipofectamine 60% 109 67 61.5% na na na 61.5% 
48 hours 
post-TF, split 
2x before TF, 
no rinse 
before adding 
complex, 
fresh media 
after 4 hours 
2/25/2007 MDA-MB-231 3:1 5 FuGene6 60% 33 7 21.2% 41 18 43.9% 32.6% 
Serum Free 
(2x media 
after 4 hours) 
2/25/2007 MDA-MB-231 6:1 5 FuGene6 60% 51 9 17.6% 36 6 16.7% 17.2% 
Serum Free 
(2x media 
after 4 hours) 
2/25/2007 MDA-MB-231 3:1 5 FuGene6 60% 40 7 17.5%    17.5% 
Regular 
Media 
2/25/2007 MDA-MB-231 6:1 5 FuGene6 60% 29 5 17.2% 39 6 15.4% 16.3% 
Regular 
Media 
2/25/2007 MDA-MB-231 6:1 5 TransIT 60% 34 10 29.4% 27 7 25.9% 27.7% 
Serum Free 
(2x media 
after 4 hours) 
2/25/2007 MDA-MB-231 3:1 5 TransIT 60% 29 6 20.7% 28 6 21.4% 21.1% 
Regular 
Media 
2/25/2007 MDA-MB-231 6:1 5 TransIT 60% 39 10 25.6% 25 10 40.0% 32.8% 
Regular 
Media 
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Table B-1 (continued). 
 
            Field 1 Field 2     
Date of 
Analysis Cell Line 
Ratio 
(Lipid:DNA) 
ug 
pGL Reagent 
% Confluent at 
Transfection 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
Average% Notes: 
2/25/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 21 7 33.3% 18 4 22.2% 27.8% 
Serum Free 
(fresh media 
after 4 hours) 
2/25/2007 MDA-MB-231 6:1 5 Lipofectamine 60% 28 1 3.6% 27 0 0.0% 1.8% 
Regular 
Media 
2/28/2007 MDA-MB-231 3:1 5 Lipofectamine 70% 33 3 9.1% 30 3 10.0% 9.5% 
Fresh media 
after 4 hours 
2/28/2007 MDA-MB-231 3:1 5 FuGene6 65% 42 7 16.7% 30 7 23.3% 20.0% 
Regular 
Media 
2/28/2007 MDA-MB-231 3:1 5 FuGene6 55% 19 4 21.1% 28 4 14.3% 17.7% 
Regular 
Media 
2/28/2007 293 3:1 5 FuGene6 80% 121 48 39.7% 135 53 39.3% 39.5% Regular Media 
3/1/2007 MDA-MB-231 3:1 5 Lipofectamine 55% 24 2 8.3% 20 3 15.0% 11.7% 
Fresh media 
after 4 hours 
3/1/2007 293 3:1 5 Lipofectamine 55% 63 10 15.9% 47 5 10.6% 13.3% Fresh media after 4 hours 
3/1/2007 293 3:1 5 FuGene6 55% 66 32 48.5% 69 24 34.8% 41.6% Regular Media 
3/8/20071 MDA-MB-231 6:1 5 TransIT 65% 28 11 39.3% 27 8 29.6% 34.5% 
Regular 
Media 
3/8/2007 MDA-MB-231 6:1 5 Lipofectamine 65% 9 1 11.1% 5 1 20.0% 15.6% 
Fresh media 
after 4 hours 
3/8/2007 MDA-MB-231 3:1 5 FuGene6 65% 33 9 27.3% 27 8 29.6% 28.5% 
Fresh media 
after 4 hours 
3/8/2007 293 6:1 5 TransIT 65% 94 58 61.7% 96 69 71.9% 66.8% Regular Media 
3/8/2007 293 6:1 5 Lipofectamine 65% 95 49 51.6% 94 63 67.0% 59.3% Fresh media after 4 hours 
3/8/2007 293 3:1 5 FuGene6 65% 134 56 41.8% 133 55 41.4% 41.6% Fresh media after 4 hours 
3/9/2007 MDA-MB-231 6:1 5 TransIT 65% 34 8 23.5% 33 8 24.2% 23.9% 
Split 2x 
before TF, 
Regular 
media 
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Table B-1 (continued). 
 
            Field 1 Field 2     
Date of 
Analysis Cell Line 
Ratio 
(Lipid:DNA) 
ug 
pGL Reagent 
% Confluent at 
Transfection 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
# of 
cells 
# of cells 
expressing 
GFP 
Transfection 
Efficiency 
(%) 
Average% Notes: 
3/9/2007 MDA-MB-231 6:1 5 Lipofectamine 65% 12 2 16.7% 14 2 14.3% 15.5% 
Split 2x 
before TF, 
Fresh media 
after 4 hours 
3/9/2007 MDA-MB-231 3:1 5 FuGene6 65% 40 9 22.5% 28 9 32.1% 27.3% 
Split 2x 
before TF, 
Fresh media 
after 4 hours 
3/9/2007 293 6:1 5 TransIT 65% 100 54 54.0% 111 57 51.4% 52.7% 
Split 2x 
before TF, 
Regular 
media 
3/9/2007 293 6:1 5 Lipofectamine 65% 64 35 54.7% 79 46 58.2% 56.5% 
Split 2x 
before TF, 
Fresh media 
after 4 hours 
3/9/2007 293 3:1 5 FuGene6 65% 112 52 46.4% 122 51 41.8% 44.1% 
Split 2x 
before TF, 
Fresh media 
after 4 hours 
 
1The top performing conditions and reagent for each cell type are shaded gray.
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Figure B-1.  Fusion Assay Results.  (A) Micrographs of fusion assay controls.  Mock is 
alpha/293 + omega/MDA-MB-231.  (B) Graph depicting the number of syncytia formed 
during fusion assay.
Appendix C. Plasmids 
 
 
Table C-1.  Plasmids Constructed and Used. 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
General Use 
Plasmids       
 pUC18 na na purchaced C-1  
 pcDNA3 na na purchaced C-2  
 pcDNA3_delNeo na na na C-3 del 2093-3199 
 EcoR (1475) pcDNA3 (BamHI, EcoRI) EcoR cDNA (BamHI, EcoRI) LA NA  
 alpha na na gift from N. Landau NA  
 omega na na gift from N. Landau NA  
 pBabeCXCR4puro na na gift from N. Landau NA  
 pcCXCR4 pcDNA3 (EcoRI) CXCR4 from pBabeCXCR4puro (EcoRI) GV C-4  
       
MoMLV Plasmids       
 pUC-Env pUC18 (PmlI, EcoRI) MoMLV env  (PmlI, EcoRI) BR NA  
 FL-39-4b pUC18 Env ExSite Mutagenesis FL NA pUC-Env del RBS 
       
3 plasmid system       
 3240 pcDNA3_delNeo (filled HindIII, filled EcoR1) 
MoMLV gag (del_psi) & 
pol (BssHII, BspEI filled) TZ C-5 
893/8213-8264, 1-214, (+g)564-6513/939; 
D135A, del psi 
 3245 pcDNA3_delNeo (filled HindIII, filled EcoR1) MoMLV env (BssHII, ?) TZ C-6 893/8213-8264, 1-214(+gc), 5403-7776/938 
 GV-1 3245 (PmlI, BspEI) FL-28 (PmlI, BspEI) GV C-7 Sst/RBS Env (Sst-14 replacing MoMLV RBS) 
 GV-2 3245 (PmlI, BspEI) MS-10 (PmlI, BspEI) GV C-8 Sst/RBS-R95D Env 
 
60 
Table C-1 (continued). 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
MoMLV Plasmids 
(continued)       
3 plasmid system 
(continued)       
 GV-31 GV-2 (BspEI, EcoRI) 838 (BspE1, EcoRI) GV C-9 Sst/RBS-R95D-Q227R-D243Y Env 
 GV-41 GV-2 (BspEI, EcoRI) 2027 (BspEI, EcoRI) GV C-10 Sst/RBS-R95D-Q227R Env 
 GV-51 GV-2 (BspEI, EcoRI) 2059 (BspEI, EcoRI) GV C-11 Sst/RBS-R95D-D243Y Env 
 GV-6 3240 (HpaI, filled BspEI) self ligation GV C-12 reduced amount of env gene in original 3240 construct 
 TS45 3245 Mutagenesis TS C-13 perfect splice donor, perfect splice acceptor 
 SDF-1a/RBS A 3245 + A flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-14 SDF-1a replacing MoMLV RBS 
 SDF-1a/RBS B 3245 + B flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-15 SDF-1a replacing MoMLV RBS 
 SDF-1a/RBS C 3245 + C flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-16 SDF-1a replacing MoMLV RBS 
 SDF-1a/RBS D 3245 + D flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-17 SDF-1a replacing MoMLV RBS 
 SDF-1a/RBS E 3245 + E flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-18 SDF-1a replacing MoMLV RBS 
 SDF-1a/RBS G 3245 + G flanking sequence (HindIII) 
SDF-1a - flanking 
sequence (HindIII) GV C-19 SDF-1a inserted just before MoMLV RBS 
 (Q123) 3245_R-less 3245 R-less ZQ C-20 893/8213-8264, 1-214(+gc), 5403-7859/938; V616* 
 TS45_R-less TS45 (BamHI, EcoRI) Q123 (BamH1, EcoRI) LA C-21 perfect splice donor, perfect splice acceptor, V616* 
 GV-1_R-less GV-1 (BamHI, EcoRI) TS45 (BamH1, EcoRI) LA C-22 Sst/RBS-V616* 
 RGD-14/RBS R-less      (45/51A mp2) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified LR51A 
RBS (BstEII, BamHI) GV C-23 RGD-14 replacing MoMLV RBS 
 Cys-Bombesin-1/RBS R-less (45/67 mp2) 
TS45_R-less 
 (BstEII, BamHI) 
PCR amplified FL67 RBS 
(BstEII, BamHI) GV C-24 
Bombesin-1 flanked by Cys replacing 
MoMLV RBS 
 Cys-Bombesin-2/RBS R-less (45/68 mp2) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified FL68 RBS 
(BstEII, BamHI) GV C-25 
Bombesin-2 flanked by Cys replacing 
MoMLV RBS 
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Table C-1 (continued). 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
MoMLV Plasmids 
(continued)       
3 plasmid system 
(continued)       
 Cys-RGD-14/RBS R-less (45/59 mp2) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified FL59 RBS 
(BstEII, BamHI) GV C-26 
RGD-14 flanked by Cys replacing MoMLV 
RBS 
 SP-11/RBS R-less  (45/53 mp3) 
TS45_R-less   
(BstEII, BamHI) 
PCR amplified LS53 RBS 
(BstEII, BamHI) GV C-27 SP-11 replacing MoMLV RBS 
 Neurotensin/RBS R-less (45/54 mp3) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified LN54 RBS 
(BstEII, BamHI) GV C-28 Neurotensin replacing MoMLV RBS 
 Oxytocin/RBS R-less  (45/49 mp3) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified LO49 RBS 
(BstEII, BamHI) GV C-29 Oxytocin replacing MoMLV RBS 
 Bombesin-14/RBS R-less (45/56-5 mp3) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified LB56-5 
RBS (BstEII, BamHI) GV C-30 Bombesin replacing MoMLV RBS 
 Endothelin/RBS R-less (45/50 mp3) 
TS45_R-less  
(BstEII, BamHI) 
PCR amplified LE50 RBS 
(BstEII, BamHI) GV C-31 Endothelin replacing MoMLV RBS 
 TS45_delRBS_R-less  (45/39-4b mp2) 
TS45_R-less (BstEII, 
BamHI) 
PCR amplified FL-39-4b 
RBS (BstEII, BamHI) GV C-32 delRBS_R-less Env 
 TS45_delRBS TS45 (BstEII, BamHI) PCR amplified FL-39-4b RBS (BstEII, BamHI) GV C-33 delRBS Env 
 GVTS45 TS45 filled MluI site (acgccgcgt) GV C-34 perfect splice donor, perfect splice acceptor, enhanced promoter activity, +c 
 GVTS45_delRBS GVTS45 (PmlI, BspEI) PCR amplified TS45_del RBS_R-less (PmlI, BspEI) GV C-35 
perfect splice donor, perfect splice acceptor, 
enhanced promoter activity, delRBS 
 TS45/HBS-1 TS45 ExSite Mutagenesis GV C-36 E127K 
 TS45/HBS-2 TS45 ExSite Mutagenesis GV C-37 E127R 
 TS45/HBS-3 TS45 ExSite Mutagenesis GV C-38 E127H 
 TS45/HBS-4 TS45 ExSite Mutagenesis GV C-39 all B=K 
 TS45/HBS-5 TS45 ExSite Mutagenesis GV C-40 all B=R 
 TS45/HBS-6 TS45 ExSite Mutagenesis GV C-41 all B=RorH 
 TS45/HBS-7 TS45 ExSite Mutagenesis GV C-42 all B=KorH 
 TS45/HBS-8 TS45 ExSite Mutagenesis GV C-43 all B=A 
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Table C-1 (continued). 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
MoMLV Plasmids 
(continued)       
2 plasmid system       
 752 pcDNA3_delNeo MoMLV gag (del_psi), pol, env TZ Y 
MoMLV gag, pol, env in pcDNA3_delNeo 
(pcDNA_MoMLV) 
 FL-28 752 Sst-14 FL Y Sst/RBS 
 MS-10 FL-28 QuikChange Mutagenesis MS NA Sst/RBS-R95D 
 H8R 752 QuikChange Mutagenesis JF NA H8R 
 838 752 (PmlI, NsiI) Natural Env Mutant  (PmlI, NsiI)  TZ NA H8R-Q227R-D243Y 
 2027 H8R Oligo Site-directed Mutagenesis TZ NA H8R-Q227R 
 2059 752 Oligo Site-directed Mutagenesis TZ NA D243Y 
 LB56-5 752 Bombesin FL Y Bombesin replacing MoMLV RBS 
 FL67 752 Cys-Bombesin-1-Cys FL Y Bombesin-1 flanked by Cys replacing MoMLV RBS 
 FL68 752 Cys-Bombesin-2-Cys FL Y Bombesin-2 flanked by Cys replacing MoMLV RBS 
 LR51A 752 RGD-14 FL Y RGD-14 replacing MoMLV RBS 
 FL59 752 Cys-RGD14-Cys FL Y RGD-14 flanked by Cys replacing MoMLV RBS 
 LN54 752 Neurotensin FL Y Neurotensin replacing MoMLV RBS 
 LO49 752 Oxytocin FL Y Oxytocin replacing MoMLV RBS 
 LE50 752 Endothelin FL Y Endothelin replacing MoMLV RBS 
 LS53 752 SP-11 FL Y SP-11 replacing MoMLV RBS 
 GV752 752 (EcoRI, SnaBI) PCR Amplified GVTS45 fragment (EcoRI, SnaBI) GV Y enhanced promoter activity 
63 
Table C-1 (continued). 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
MoMLV Plasmids 
(continued)       
2 plasmid system 
(continued)       
 GV752_delRBS GV752 (PmlI, BspEI) 
PCR amplified 
TS45_delRBS_R-less 
fragment (PmlI, BspEI) 
GV Y delRBS, enhanced promoter activity 
 GV752/HBS-1 GV752 
PCR Amplified 
TS45/HBS-1 fragment 
(PmlI, BspEI) 
GV Y E127K 
 GV752/HBS-2 GV752 
PCR Amplified 
TS45/HBS-2 fragment 
(PmlI, BspEI) 
GV Y E127R 
 GV752/HBS-3 GV752 
PCR Amplified 
TS45/HBS-3 fragment 
(PmlI, BspEI) 
GV Y E127H 
 GV752/HBS-4 GV752 
PCR Amplified 
TS45/HBS-4 fragment 
(PmlI, BspEI) 
GV Y all B=K 
 GV752/HBS-5 GV752 
PCR Amplified 
TS45/HBS-5 fragment 
(PmlI, BspEI) 
GV Y all B=R 
 GV752/HBS-6 GV752 
PCR Amplified 
TS45/HBS-6 fragment 
(PmlI, BspEI) 
GV Y all B=RorH 
 GV752/HBS-7 GV752 
PCR Amplified 
TS45/HBS-7 fragment 
(PmlI, BspEI) 
GV Y all B=KorH 
 GV752/HBS-8 GV752 
PCR Amplified 
TS45/HBS-8 fragment 
(PmlI, BspEI) 
GV Y all B=A 
 GV752_delRBS/HBS-1 GV752_delRBS  (MluI, BspEI) 
PCR Amplified 
TS45/HBS-1 fragment 
(+MluI, BspEI) 
GV Y E127K, del RBS 
 GV752_delRBS/HBS-2 GV752_delRBS  (MluI, BspEI) 
PCR Amplified 
TS45/HBS-2 fragment 
(+MluI, BspEI) 
GV Y E127R, del RBS 
 GV752_delRBS/HBS-3 GV752_delRBS  (MluI, BspEI) 
PCR Amplified 
TS45/HBS-3 fragment 
(+MluI, BspEI) 
GV Y E127H, del RBS 
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 Table C-1 (continued). 
 
Category Construct Name Backbone Insert Constructed By Map Notes 
MoMLV Plasmids 
(continued)       
2 plasmid system 
(continued)       
 GV752_delRBS/HBS-4 GV752_delRBS  (MluI, BspEI) 
PCR Amplified 
TS45/HBS-4 fragment 
(+MluI, BspEI) 
GV Y all B=K, del RBS 
 GV752_delRBS/HBS-5 GV752_delRBS (MluI, BspEI) 
PCR Amplified 
TS45/HBS-5 fragment 
(+MluI, BspEI) 
GV Y all B=R, del RBS 
 GV752_delRBS/HBS-6 GV752_delRBS (MluI, BspEI) 
PCR Amplified 
TS45/HBS-6 fragment 
(+MluI, BspEI) 
GV Y all B=RorH, del RBS 
 GV752_delRBS/HBS-7 GV752_delRBS (MluI, BspEI) 
PCR Amplified 
TS45/HBS-7 fragment 
(+MluI, BspEI) 
GV Y all B=KorH, del RBS 
 GV752_delRBS/HBS-8 GV752_delRBS (MluI, BspEI) 
PCR Amplified 
TS45/HBS-8 fragment 
(+MluI, BspEI) 
GV Y all B=A, del RBS 
 
 
 
 
pUC18
2686 bp
ALPHA
Amp(r)
P(BLA)
P(LAC)
ORI
Aat II (2622)
Acc 65I (439)
Acc I (419)
Afl III (807)
Ahd I (1700)
Alw NI (1223)
Apa BI (187)
Apo I (451)
Ava I (435)
Bam HI (430)
Ban II (449)
Bbe I (240)
Bcg I (2239)
Bpm I (1770)
Bsa I (1761)
Bsa XI (652)
Bse YI (1111)
BspMI (405)
Bsr FI (1780)
Bst API (186)
Eco ICRI (447)
Eco O109I (2676)
Eco RI (451)
Hae IV (1719)
Hinc II (420)
Hin dIII (400)
Kas I (236)
Kpn I (443)
Nar I (237)
Nde I (185)
Nli 3877I (439)
Pci I (807)
Pfo I (47)
Pss I (2679)
Pst I (416)
Sac I (449)
Sal I (418)
Sap I (691)
Sbf I (416)
Sca I (2180)
Sfo I (238)
Sma I (437)
Sph I (410)
Ssp I (2504)
Uth SI (436)
Xba I (424)
Xma I (435)
Xmn I (2299)
Zra I (2620)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-1.  pUC18.
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pcDNA3
5446 bp
M CS (889)
NEOr
AMPr
SV40 pA
BGH pA
CMV prom oter
SV40 prom oter
T7 Promoter
Sp6 Prom oter
SV40 ORI
Acc 65I (896)Ahd I (4524)
Alo I (1582)
Apa I (994)
Avr II (2070)
Bam HI (908)
Bbe I (2283)
Bbr 7I (1237)
Bbs I (1232)
Bcg I (5063)
Bgl II (13)
Bpu 10I (181)
Bse RI (2066)
Bsm I (3200)
Bss HII (2677)
Bst BI (2962)
Bst Z17I (3252)
Dra III (1546)
Eco RI (939)
Eco RV (951)
Fal I (2620)
Hin dIII (890)
Kas I (2279)
Kpn I (900)
Mfe I (162)
Mlu I (229)
Msc I (2362)
Nar I (2280)
Nde I (485)
Not I (966)
Nru I (209)
Pci I (3631)
Pfo I (3055) Psp OMI (990)
Pvu I (4894)
Rsr II (2796)
Sca I (5004)
Sci I (974)
Sex AI (1837)
Sfo I (2281)
Sma I (2093)
Sna BI (591)
Ssp I (5328)
Stu I (2069)
Tth 111I (2398)
Uth SI (2092)
Xba I (984)
Xho I (972)
Xma I (2091)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-2. pcDNA3.
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pcDNA3 del NEOr
4339 bp
M CS (889)
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SV40 ORI
Acc 65I (896)
Ahd I (3417)
Alo I (1582)
Apa I (994)
Ava I (972)
Avr II (2070)
Bam HI (908)
Bbr 7I (1237)
Bbs I (1232)
Bcg I (3956)
Bcl I (1030)
Bgl II (13)
Bpl I (2037)
Bpm I (3487)
Bpu 10I (181)
Bsa BI (953)
Bse RI (2066)
Bst Z17I (2145)
Dra III (1546)
Eco RI (939)
Eco RV (951)
Fsp I (3639)
Hae IV (3436)
Hin dIII (890)
Kpn I (900)
Mfe I (162)
Mlu I (229)
Nae I (1440)
Nde I (485)
Ngo MIV (1438)
Nli 3877I (976)
Not I (966)
Nru I (209)
Pci I (2524)
Psi I (1671)
Psp OMI (990)
Pst I (948)
Pvu I (3787)
Sap I (2408)
Sca I (3897)
Sci I (974)
Sex AI (1837)
Sna BI (591)
Ssp I (4221)
Stu I (2069)
Xba I (984)
Xcm I (2100)
Xho I (972)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-3. pcDNA3_delNeo.
68 
 
 
 
69 
pcCXCR4
6584 bp
NEOr
AMPr
SV40 pA
BGH pA
CMV prom oter
SV40 promoter
T7 Prom oter
Sp6 Prom oter
SV40 ORI
CXCR-4 (1010)
Acc 65I (896)
Afl II (947)
Ahd I (5662)
Ale I (1965)
Apa I (2132)
Avr II (3208)
Bbe I (3421)
Bcg I (6201)
Bgl II (13)
Bsg I (1227)
Bsm I (4338)
Bss HII (3815)
Bst BI (4100)
Bst Z17I (4390)
Dra III (2684)
Eco NI (1335)
Eco RV (2089)
Fal I (3758)
Hin dIII (890)
Kas I (3417)
Kpn I (900)
Mfe I (162)
Mlu I (229)
Nar I (3418)
Nde I (485)
Not I (2104)
Nru I (209)
Pci I (4769)
Psh AI (1731)
Psp OMI (2128)
Pvu I (6032)
Rsr II (3934)
Sca I (6142)
Sci I (2112)
Sex AI (2975)
Sfo I (3419)
Sma I (3231)
Sna BI (591)
Ssp I (6466)
Stu I (3207)
Tth 111I (3536)
Uth SI (3230)
Xba I (2122)
Xho I (2110)
Xma I (3229)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-4. pcCXCR4.
 
 
3240
10512 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
pro-tRNA primer binding si te (1091)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
M oM LV(6513)/pcDNA3 del Neo(939) junction (7112)
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SV40 ORI
D135A (6876)
Q174* (6993)
extra g (1160)
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
Variation 1 (2447)
Variation 2 (2853)
del psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsm I (1859)
Bsr GI (1519)
Bst Z17I (8318)
Cla I (5580)
Eco RI (7112)
Fal I (3673)
Fsp I (9812)
Hin dIII (5493)
Hpa I (6417)
Mlu I (229)
Nae I (7613)
Ngo MIV (7611)
Not I (7139)
Pci I (8697)
Pfl MI (2432)
Pml I (6331) Psh AI (2025)
Psi I (7844)
Sac II (5551)
San DI (1717)
Sfi I (5988)
Sna BI (591)
Ssp I (10394)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-5. 3240.
70 
 
 
 
 
 
3245
6937 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2323)
SU-RBD (1635)
SU-CTD (2460)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3536)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter putative RBS (env aa 72-85) (1848)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4180)
Avr II (4668)
Bam HI (2297)
Bbe I (950)
Bbr 7I (3835)
Bbs I (3830)
Bcl I (3628)
Bpl I (4635)
Bsa BI (3551)
Bsm I (3425)
Bsp EI (2269)
Bst EII (1683)
Bst Z17I (4743)
Cla I (3435)
Eag I (3564)
Eco RI (3537)
Fsp I (6237)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4038)
Nar I (947)
Nde I (485)
Ngo MIV (4036)
Not I (3564)
Nru I (209)
Pci I (5122)
Pfl MI (2422)
Pml I (1492)
Psi I (4269)
Psr I (3038)
Pst I (3546)
Pvu I (6385)
Sci I (3572)
Sfo I (948)
Sgr AI (2454)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6819)
Stu I (4667)
Xho I (3570)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-6. 3245.
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GV-1
6961 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2347)
SU-RBD (1635)
SU-CTD (2484)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3560)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1848)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4204)
Avr II (4692)
Bam HI (2321)
Bbe I (950)
Bcl I (3652)
Bpl I (4659)
Bpu 10I (181)
Bsa BI (3575)
Bsm I (3449)
Bsp EI (2293)
Bst EII (1683)
Cla I (3459)
Eag I (3588)
Eco RI (3561) Fal I (1890)
Fsp I (6261)
Kas I (946)
Mfe I (162)
Nae I (4062)
Nar I (947)
Nde I (485)
Ngo MIV (4060)
Not I (3588)
Nru I (209)
Pci I (5146)
Pfl MI (2446)
Pml I (1492)
Psi I (4293)
Psr I (3062)
Pst I (3570)
Pvu I (6409)
Sci I (3596)
Sfo I (948)
Sgr AI (2478)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6843)
Stu I (4691)
Xho I (3594)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-7. GV-1.
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GV-2
6961 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2347)
SU-RBD (1635)
SU-CTD (2484)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3560)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1849)
SV40 ORI
2 extra nt (gc) (1160)
R95D (1941)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4204)
Avr II (4692)
Bam HI (2321)
Bbe I (950)
Bcl I (3652)
Bpl I (4659)
Bpu 10I (181)
Bsa BI (3575)
Bsm I (3449)
Bsp EI (2293)
Bst EII (1683)
Cla I (3459)
Eag I (3588)
Eco RI (3561) Fal I (1890)
Fsp I (6261)
Kas I (946)
Mfe I (162)
Nae I (4062)
Nar I (947)
Nde I (485)
Ngo MIV (4060)
Not I (3588)
Nru I (209)
Pci I (5146)
Pfl MI (2446)
Pml I (1492)
Psi I (4293)
Psr I (3062)
Pst I (3570)
Pvu I (6409)
Sci I (3596)
Sfo I (948)
Sgr AI (2478)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6843)
Stu I (4691)
Xho I (3594)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-8. GV-2.
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GV-3(1)
6961 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2347)
SU-RBD (1635)
SU-CTD (2484)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3560)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1849)
SV40 ORI
2 extra nt (gc) (1160)
R95D (1941)
Q227R (2337)
D243Y (2385)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4204)
Avr II (4692)
Bam HI (2321)
Bbe I (950)
Bcl I (3652)
Bpl I (4659)
Bpu 10I (181)
Bsa BI (3575)
Bsm I (3449)
Bsp EI (2293)
Bst EII (1683)
Cla I (3459)
Eag I (3588)
Eco RI (3561) Fal I (1890)
Fsp I (6261)
Kas I (946)
Mfe I (162)
Nae I (4062)
Nar I (947)
Nde I (485)
Ngo MIV (4060)
Not I (3588)
Nru I (209)
Pci I (5146)
Pfl MI (2446)
Pml I (1492)
Psi I (4293)
Psr I (3062)
Pst I (3570)
Pvu I (6409)
Sci I (3596)
Sfo I (948)
Sgr AI (2478)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6843)
Stu I (4691)
Xho I (3594)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-9. GV-31.
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GV-4(1)
6961 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2347)
SU-RBD (1635)
SU-CTD (2484)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3560)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1849)
SV40 ORI
2 extra nt (gc) (1160)
R95D (1941)
Q227R (2337)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4204)
Avr II (4692)
Bam HI (2321)
Bbe I (950)
Bcl I (3652)
Bpl I (4659)
Bpu 10I (181)
Bsa BI (3575)
Bsm I (3449)
Bsp EI (2293)
Bst EII (1683)
Cla I (3459)
Eag I (3588)
Eco RI (3561) Fal I (1890)
Fsp I (6261)
Kas I (946)
Mfe I (162)
Nae I (4062)
Nar I (947)
Nde I (485)
Ngo MIV (4060)
Not I (3588)
Nru I (209)
Pci I (5146)
Pfl MI (2446)
Pml I (1492)
Psi I (4293)
Psr I (3062)
Pst I (3570)
Pvu I (6409)
Sci I (3596)
Sfo I (948)
Sgr AI (2478)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6843)
Stu I (4691)
Xho I (3594)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-10. GV-41.
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GV-5(1)
6961 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2347)
SU-RBD (1635)
SU-CTD (2484)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3560)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1849)
SV40 ORI
2 extra nt (gc) (1160)
R95D (1941)
D243Y (2385)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4204)
Avr II (4692)
Bam HI (2321)
Bbe I (950)
Bcl I (3652)
Bpl I (4659)
Bpu 10I (181)
Bsa BI (3575)
Bsm I (3449)
Bsp EI (2293)
Bst EII (1683)
Cla I (3459)
Eag I (3588)
Eco RI (3561) Fal I (1890)
Fsp I (6261)
Kas I (946)
Mfe I (162)
Nae I (4062)
Nar I (947)
Nde I (485)
Ngo MIV (4060)
Not I (3588)
Nru I (209)
Pci I (5146)
Pfl MI (2446)
Pml I (1492)
Psi I (4293)
Psr I (3062)
Pst I (3570)
Pvu I (6409)
Sci I (3596)
Sfo I (948)
Sgr AI (2478)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6843)
Stu I (4691)
Xho I (3594)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-11. GV-51.
 
 
GV-6
9821 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
pro-tRNA primer binding site (1091)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
M oM LV(6513)/pcDNA3 del  Neo(939) junction (6421)
Unique BspEI cut site (6417)
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SV40 ORI
extra g (1160)
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
Variation 1 (2447)
Variation 2 (2853)
del psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsm I (1859)
Bsr GI (1519)
Bst Z17I (7627)
Cla I (5580)
Eco RI (6421)
Fal I (3673)
Fsp I (9121)
Hin dIII (5493)
Mlu I (229)
Nae I (6922)
Ngo MIV (6920)
Not I (6448)
Pci I (8006)
Pfl MI (2432)
Pml I (6331)
Psh AI (2025)
Psi I (7153)
Sac II (5551)
San DI (1717)
Sca I (9379)
Sfi I (5988)
Sna BI (591)
Ssp I (9703)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-12. GV-6.
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TS45
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-13. TS45.
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SDF-1a/RBS A
7054 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-CTD (2577)
SU-PRR (2440)
SU-RBD (1635)
M oM LV(7776)/pcDNA3 del  Neo(938) junction (3653)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a/RBS A (1782)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding s ite
Afl II (1990)
Ale I (1787)
Alo I (4297)
Avr II (4785)
Bam HI (2414)
Bbe I (950)
Bbr 7I (3952)
Bbs I (3947)
Bcl I (3745)
Bpu 10I (181)
Bsa BI (3668)
Bsm I (3542)
Bsp EI (2386)
Bst BI (1868)
Bst EII (1683)
Bst Z17I (4860)
Cla I (3552)
Eag I (3681)
Eco RI (3654)
Fsp I (6354)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4155)
Nar I (947)
Nde I (485)
Ngo MIV (4153)
Not I (3681)
Nru I (209)
Pci I (5239)
Pfl MI (2539)
Pml I (1492)
Psi I (4386)
Psr I (3155)
Pvu I (6502)
Sfo I (948)
Sgr AI (2571)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6936)
Stu I (4784)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-14. SDF-1a/RBS A.
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SDF-1a/RBS B
7075 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-CTD (2598)
SU-PRR (2461)
SU-RBD (1635)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3674)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a/RBS B (1815)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding site
Afl II (1990)
Alo I (4318)
Avr II (4806)
Bam HI (2435)
Bbe I (950)
Bbr 7I (3973)
Bbs I (3968)
Bcl I (3766)
Bpl I (4773)
Bpu 10I (181)
Bsa BI (3689)
Bsm I (3563)
Bsp EI (2407)
Bst BI (1868)
Bst EII (1683)
Bst Z17I (4881)
Cla I (3573)
Eag I (3702)
Eco NI (2014)
Eco RI (3675)
Fsp I (6375)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4176)
Nar I (947)
Nde I (485)
Ngo MIV (4174)
Not I (3702)
Nru I (209)
Pci I (5260)
Pfl MI (2560)
Pml I (1492)
Psi I (4407)
Psr I (3176)
Pvu I (6523)
Sfo I (948)
Sgr AI (2592)
Sna BI (591)
Sse 8647I (1415)
Stu I (4805)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-15. SDF-1a/RBS B.
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SDF-1a/RBS C
7045 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-PRR (2431)
SU-CTD (2568)
SU-RBD (1635)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3644)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a/RBS C (1809)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding site
Afl II (1981)
Alo I (4288)
Avr II (4776)
Bam HI (2405)
Bbe I (950)
Bbr 7I (3943)
Bbs I (3938)
Bcl I (3736)
Bpu 10I (181)
Bsa BI (3659)
Bsm I (3533)
Bsp EI (2377)
Bst BI (1859)
Bst EII (1683)
Bst Z17I (4851)
Cla I (3543)
Eag I (3672)
Eco RI (3645)
Fsp I (6345)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4146)
Nar I (947)
Nde I (485)
Ngo MIV (4144)
Not I (3672)
Nru I (209)
Pci I (5230)
Pfl MI (2530)
Pml I (1492)
Psi I (4377)
Psr I (3146)
Pvu I (6493)
Sfo I (948)
Sgr AI (2562)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6927)
Stu I (4775)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-16. SDF-1a/RBS C.
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SDF-1a/RBS D
7054 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-CTD (2577)
SU-PRR (2440)
SU-RBD (1635)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3653)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a/RBS D (1785)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding site
Afl II (1990)
Ale I (1787)
Alo I (4297)
Avr II (4785)
Bam HI (2414)
Bbe I (950)
Bbr 7I (3952)
Bbs I (3947)
Bcl I (3745)
Bpl I (4752)
Bpu 10I (181)
Bsa BI (3668)
Bsm I (3542)
Bsp EI (2386)
Bst BI (1868)
Bst EII (1683)
Bst Z17I (4860)
Cla I (3552)
Eag I (3681)
Eco RI (3654)
Fsp I (6354)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4155)
Nar I (947)
Nde I (485)
Ngo MIV (4153)
Not I (3681)
Nru I (209)
Pci I (5239)
Pfl MI (2539)
Pml I (1492)
Psi I (4386)
Psr I (3155)
Pvu I (6502)
Sci I (3689)
Sfo I (948)
Sgr AI (2571)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6936)
Stu I (4784)
Xho I (3687)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-17. SDF-1a/RBS D.
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SDF-1a/RBS E
7045 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
M oM LV(7776)/pcDNA3 del  Neo(938) junction (3644)
SU-CTD (2568)
SU-PRR (2431)
SU-RBD (1635)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a/RBS E (1809)
SV40 ORI
2 extra nt (gc) (1160)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding s ite
Afl II (1981)
Alo I (4288)
Avr II (4776)
Bam HI (2405)
Bbe I (950)
Bbr 7I (3943)
Bbs I (3938)
Bcl I (3736)
Bpl I (4743)
Bpu 10I (181)
Bsa BI (3659)
Bsm I (3533)
Bsp EI (2377)
Bst BI (1859)
Bst EII (1683)
Bst Z17I (4851)
Cla I (3543)
Eag I (3672)
Eco RI (3645)
Fsp I (6345)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4146)
Nar I (947)
Nde I (485)
Ngo MIV (4144)
Not I (3672)
Nru I (209)
Pci I (5230)
Pfl MI (2530)
Pml I (1492)
Psi I (4377)
Psr I (3146)
Pvu I (6493)
Sci I (3680)
Sfo I (948)
Sgr AI (2562)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6927)
Stu I (4775)
Xho I (3678)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-18. SDF-1a/RBS E.
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SDF-1a/RBS G
7150 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3749)
SU-CTD (2673)
SU-PRR (2536)
SU-RBD (1635)
pcDNA3 del Neo(893)/M oM LV(8213) junction (89
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SDF-1a G RBS (1869)
Putative M oM LV RBS (env aa 72-85) (20
SV40 ORI
2 extra nt (gc) (1160)
P79R (1869)
Repeat of S78, P79R, & G80 (2079)
POL
gp70 SU
p15e TM
R-peptide
SDF-1a
pro-tRNA prim er binding site
Afl II (2038)
Alo I (4393)
Avr II (4881)
Bbe I (950)
Bbr 7I (4048)
Bbs I (4043)
Bcl I (3841)
Bpl I (4848)
Bsa BI (3764)
Bsm I (3638)
Bsp EI (2482)
Bst BI (1916)
Bst EII (1683)
Bst Z17I (4956)
Cla I (3648)
Eag I (3777)
Eco NI (2062)
Eco RI (3750)
Fsp I (6450)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4251)
Nar I (947)
Nde I (485)
Ngo MIV (4249)
Not I (3777)
Nru I (209)
Pci I (5335)
Pfl MI (2635)
Pml I (1492)
Psi I (4482)
Psr I (3251)
Pvu I (6598)
Sac II (1872)
Sfo I (948)
Sgr AI (2667)
Sna BI (591)
Sse 8647I (1415)
Ssp I (7032)
Stu I (4880)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-19. SDF-1a/RBS G.
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3245 R-less
7010 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-RBD (1635)
SU-PRR (2323)
SU-CTD (2460)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3610)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter putative RBS (env aa 72-85) (1848)
SV40 ORI
2 extra nt after ligation (gc) (1160)
V616* (3483)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4253)
Avr II (4741)
Bam HI (2297)
Bbe I (950)
Bbr 7I (3908)
Bbs I (3903)
Bcl I (3701)
Bpl I (4708)
Bsa BI (3624)
Bsm I (3425)
Bsp EI (2269)
Bst EII (1683)
Bst Z17I (4816)
Cla I (3435)
Eag I (3637)
Eco RI (3610)
Fsp I (6310)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4111)
Nar I (947)
Nde I (485)
Ngo MIV (4109)
Not I (3637)
Nru I (209)
Pci I (5195)
Pfl MI (2422)
Pml I (1492)
Psi I (4342)
Psr I (3038)
Pst I (3619)
Pvu I (6458)
Sci I (3645)
Sfo I (948)
Sgr AI (2454)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6892)
Stu I (4740)
Xho I (3643)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-20. 3245 R-less (Q123).
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TS45 R-less
7012 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3577)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3611)
SU-CTD (2462)
SU-PRR (2325)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3485)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Aar I (1153)
Alo I (4255)
Avr II (4743)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3910)
Bbs I (3905)
Bcl I (3703)
Bpl I (4710)
Bsa BI (3626)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4818)
Cla I (3437)
Eag I (3639)
Eco RI (3612)
Fsp I (6312)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4113)
Nar I (947)
Nde I (485)
Ngo MIV (4111)
Not I (3639)
Nru I (209)
Pci I (5197)
Pfl MI (2424)
Pml I (1494)
Psi I (4344)
Psr I (3040)
Pvu I (6460)
Sbf I (1150)
Sci I (3647)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6894)
Stu I (4742)
Xho I (3645)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-21. TS45 R-less.
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GV-1 R-less
7033 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (1246)
Repeat Region (946)
SU-RBD (1635)
SU-PRR (2346)
SU-CTD (2483)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3633)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (1847)
SV40 ORI
2 extra nt after ligation (gc) (1160)
V616* (3506)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Alo I (4276)
Avr II (4764)
Bam HI (2320)
Bbe I (950)
Bcl I (3724)
Bpl I (4731)
Bpu 10I (181)
Bsa BI (3647)
Bsm I (3448)
Bsp EI (2292)
Bst EII (1683)
Cla I (3458)
Eag I (3660)
Eco RI (3633) Fal I (1889)
Fsp I (6333)
Kas I (946)
Mfe I (162)
Nae I (4134)
Nar I (947)
Nde I (485)
Ngo MIV (4132)
Not I (3660)
Nru I (209)
Pci I (5218)
Pfl MI (2445)
Pml I (1492)
Psi I (4365)
Psr I (3061)
Pst I (3642)
Pvu I (6481)
Sci I (3668)
Sfo I (948)
Sgr AI (2477)
Sna BI (591)
Sse 8647I (1415)
Ssp I (6915)
Stu I (4763)
Xho I (3666)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-22. GV-1 R-less.
87 
 
 
 
 
 
RGD-14/RBS R-less
7036 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3601)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3635)
SU-CTD (2486)
SU-PRR (2349)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
RGD/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3509)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4279)
Avr II (4767)
Bam HI (2323)
Bbr 7I (3934)
Bbs I (3929)
Bcl I (3727)
Bpl I (4734)
Bpu 10I (181)
Bsa BI (3650)
Bsm I (3451)
Bsp EI (2295)
Bst EII (1685)
Cla I (3461)
Eag I (3663)
Eco RI (3636)
Fsp I (6336)
Mfe I (162)
Nae I (4137)
Nde I (485)
Ngo MIV (4135)
Not I (3663)
Nru I (209)
Pci I (5221)
Pfl MI (2448)
Pml I (1494)
Psi I (4368)
Psr I (3064)
Pvu I (6484)
Sac II (1883)
Sbf I (1150)
Sci I (3671)
Sgr AI (2480)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6918)
Stu I (4766)
Xho I (3669)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-23. RGD-14/RBS R-less (45/51A mp2).
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Cys-Bom-1/RBS R-less
7048 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3613)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3647)
SU-CTD (2498)
SU-PRR (2361)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-Bom-1/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3521)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4291)
Avr II (4779)
Bam HI (2335)
Bbe I (950)
Bbr 7I (3946)
Bbs I (3941)
Bcl I (3739)
Bpl I (4746)
Bpu 10I (181)
Bsa BI (3662)
Bsm I (3463)
Bsp EI (2307)
Bst EII (1685)
Cla I (3473)
Eag I (3675)
Eco RI (3648)
Fsp I (6348)
Kas I (946)
Mfe I (162)
Nae I (4149)
Nar I (947)
Nde I (485)
Ngo MIV (4147)
Not I (3675)
Nru I (209)
Pci I (5233)
Pml I (1494)
Psi I (4380)
Psr I (3076)
Pvu I (6496)
Sbf I (1150)
Sci I (3683)
Sfo I (948)
Sgr AI (2492)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6930)
Stu I (4778)
Xho I (3681)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-24. Cys-Bombesin-1/RBS R-less (45/67 mp2).
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Cys-Bom-2/RBS R-less
7060 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3625)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3659)
SU-CTD (2510)
SU-PRR (2373)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-Bom-2/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3533)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4303)
Avr II (4791)
Bam HI (2347)
Bbe I (950)
Bbr 7I (3958)
Bbs I (3953)
Bcl I (3751)
Bpl I (4758)
Bpu 10I (181)
Bsa BI (3674)
Bsm I (3475)
Bsp EI (2319)
Bst EII (1685)
Cla I (3485)
Eag I (3687)
Eco RI (3660)
Fal I (1928)
Fsp I (6360)
Hin dIII (1910)
Kas I (946)
Mfe I (162)
Nae I (4161)
Nar I (947)
Nde I (485)
Ngo MIV (4159)
Not I (3687)
Nru I (209)
Pci I (5245)
Pml I (1494)
Psi I (4392)
Psr I (3088)
Pvu I (6508)
Sbf I (1150)
Sci I (3695)
Sfo I (948)
Sgr AI (2504)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6942)
Stu I (4790)
Xho I (3693)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-25. Cys-Bombesin-2/RBS R-less (45/68 mp2).
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Cys-RGD/RBS R-less
7033 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3598)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3632)
SU-CTD (2483)
SU-PRR (2346)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-RGD/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3506)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4276)
Avr II (4764)
Bam HI (2320)
Bbr 7I (3931)
Bbs I (3926)
Bcl I (3724)
Bpl I (4731)
Bpu 10I (181)
Bsa BI (3647)
Bsm I (3448)
Bsp EI (2292)
Bst EII (1685)
Bst Z17I (4839)
Cla I (3458)
Eag I (3660)
Eco RI (3633)
Fsp I (6333)
Mfe I (162)
Nae I (4134)
Nde I (485)
Ngo MIV (4132)
Not I (3660)
Nru I (209)
Pci I (5218)
Pfl MI (2445)
Pml I (1494)
Psi I (4365)
Psr I (3061)
Pvu I (6481)
Sac II (1883)
Sbf I (1150)
Sci I (3668)
Sgr AI (2477)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6915)
Stu I (4763)
Xho I (3666)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-26. Cys-RGD-14/RBS R-less (45/59 mp2).
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SP-11/RBS R-less
7027 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3592)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3626)
SU-CTD (2477)
SU-PRR (2340)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter SP/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3500)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Aar I (1153)
Alo I (4270)
Avr II (4758)
Bam HI (2314)
Bbe I (950)
Bbr 7I (3925)
Bbs I (3920)
Bbv CI (1870)
Bcl I (3718)
Bpl I (4725)
Bsa BI (3641)
Bsm I (3442)
Bsp EI (2286)
Bst EII (1685)
Cla I (3452)
Eag I (3654)
Eco RI (3627)
Fsp I (6327)
Kas I (946)
Mfe I (162)
Nae I (4128)
Nar I (947)
Nde I (485)
Ngo MIV (4126)
Not I (3654)
Pci I (5212)
Pfl MI (2439)
Pml I (1494)
Psi I (4359)
Psr I (3055)
Pvu I (6475)
Sbf I (1150)
Sci I (3662)
Sfo I (948)
Sgr AI (2471)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6909)
Stu I (4757)
Xho I (3660)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-27. SP-11/RBS R-less (45/53 mp3).
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NT/RBS R-less
7030 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3595)
M oM LV(7850)/pcDNA3 del  Neo(938) junction (3629)
SU-CTD (2480)
SU-PRR (2343)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
NT/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3503)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding s ite
Aar I (1153)
Alo I (4273)
Avr II (4761)
Bam HI (2317)
Bbe I (950)
Bbr 7I (3928)
Bbs I (3923)
Bcl I (3721)
Bpl I (4728)
Bpu 10I (181)
Bsa BI (3644)
Bsm I (3445)
Bsp EI (2289)
Bst EII (1685)
Cla I (3455)
Eag I (3657)
Eco RI (3630)
Fsp I (6330)
Kas I (946)
Mfe I (162)
Nae I (4131)
Nar I (947)
Nde I (485)
Ngo MIV (4129)
Not I (3657)
Nru I (209)
Pci I (5215)
Pfl MI (2442)
Pml I (1494)
Psi I (4362)
Psr I (3058)
Pvu I (6478)
Sac II (1878)
Sbf I (1150)
Sci I (3665)
Sfo I (948)
Sgr AI (2474)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6912)
Stu I (4760)
Xho I (3663)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-28. Neurotensin/RBS R-less (45/54 mp3).
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OT/RBS R-less
7012 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3577)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3611)
SU-CTD (2462)
SU-PRR (2325)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
OT/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3485)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4255)
Avr II (4743)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3910)
Bbs I (3905)
Bcl I (3703)
Bpl I (4710)
Bpu 10I (181)
Bsa BI (3626)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4818)
Cla I (3437)
Eag I (3639)
Eco RI (3612)
Fsp I (6312)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4113)
Nar I (947)
Nde I (485)
Ngo MIV (4111)
Not I (3639)
Nru I (209)
Pci I (5197)
Pfl MI (2424)
Pml I (1494)
Psi I (4344)
Psr I (3040)
Pvu I (6460)
Sbf I (1150)
Sci I (3647)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6894)
Stu I (4742)
Xho I (3645)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-29. Oxytocin/RBS R-less (45/49 mp3).
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Bom/RBS R-less
7036 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3601)
M oM LV(7850)/pcDNA3 del  Neo(938) junction (3635)
SU-CTD (2486)
SU-PRR (2349)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Bom/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3509)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding s ite
Aar I (1153)
Alo I (4279)
Avr II (4767)
Bam HI (2323)
Bbe I (950)
Bbr 7I (3934)
Bbs I (3929)
Bcl I (3727)
Bpl I (4734)
Bpu 10I (181)
Bsa BI (3650)
Bsm I (3451)
Bsp EI (2295)
Bst EII (1685)
Cla I (3461)
Eag I (3663)
Eco RI (3636)
Fsp I (6336)
Kas I (946)
Mfe I (162)
Nae I (4137)
Nar I (947)
Nde I (485)
Ngo MIV (4135)
Not I (3663)
Nru I (209)
Pci I (5221)
Pml I (1494)
Psi I (4368)
Psr I (3064)
Pvu I (6484)
Sbf I (1150)
Sci I (3671)
Sfo I (948)
Sgr AI (2480)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6918)
Stu I (4766)
Xho I (3669)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-30. Bombesin/RBS R-less (45/56-5 mp3).
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Endo/RBS R-less
7048 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3613)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3647)
SU-CTD (2498)
SU-PRR (2361)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Endo/RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3521)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4291)
Avr II (4779)
Bam HI (2335)
Bbe I (950)
Bbr 7I (3946)
Bbs I (3941)
Bcl I (3739)
Bpl I (4746)
Bpu 10I (181)
Bsa BI (3662)
Bsm I (3463)
Bsp EI (2307)
Bst EII (1685)
Bst Z17I (4854)
Cla I (3473)
Eag I (3675)
Eco RI (3648)
Fsp I (6348)
Kas I (946)
Mfe I (162)
Nae I (4149)
Nar I (947)
Ngo MIV (4147)
Not I (3675)
Nru I (209)
Pci I (5233)
Pfl MI (2460)
Pml I (1494)
Psi I (4380)
Psr I (3076)
Pvu I (6496)
Sbf I (1150)
Sci I (3683)
Sfo I (948)
Sgr AI (2492)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6930)
Stu I (4778)
Xho I (3681)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-31. Endothelin-1/RBS R-less (45/50 mp3).
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TS45 del RBS R-less
6979 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
U3 (incomplete) (3544)
M oM LV(7850)/pcDNA3 del Neo(938) junction (3579)
SU-CTD (2429)
SU-PRR (2292)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
V616* (3452)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding s ite
Aar I (1153)
Alo I (4222)
Avr II (4710)
Bam HI (2266)
Bbe I (950)
Bbr 7I (3877)
Bbs I (3872)
Bcl I (3670)
Bpl I (4677)
Bpu 10I (181)
Bsa BI (3593)
Bsm I (3394)
Bsp EI (2238)
Bst EII (1685)
Bst Z17I (4785)
Cla I (3404)
Eag I (3606)
Eco RI (3579)
Fsp I (6279)
Kas I (946)
Mfe I (162)
Nae I (4080)
Nar I (947)
Nde I (485)
Ngo MIV (4078)
Not I (3606)
Nru I (209)
Pci I (5164)
Pfl MI (2391)
Pml I (1494)
Psi I (4311)
Psr I (3007)
Pvu I (6427)
Sbf I (1150)
Sci I (3614)
Sfo I (948)
Sgr AI (2423)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6861)
Stu I (4709)
Xho I (3612)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-32. TS45_delRBS R-less (45/39-4b mp2).
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TS45 del RBS
6906 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (946)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3504)
SU-CTD (2429)
SU-PRR (2292)
SU-RBD (1637)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4149)
Avr II (4637)
Bam HI (2266)
Bbe I (950)
Bbr 7I (3804)
Bbs I (3799)
Bcl I (3597)
Bpl I (4604)
Bpu 10I (181)
Bsa BI (3520)
Bsm I (3394)
Bsp EI (2238)
Bst EII (1685)
Bst Z17I (4712)
Cla I (3404)
Eag I (3533)
Eco RI (3506)
Fsp I (6206)
Kas I (946)
Mfe I (162)
Nae I (4007)
Nar I (947)
Nde I (485)
Ngo MIV (4005)
Not I (3533)
Nru I (209)
Pci I (5091)
Pfl MI (2391)
Pml I (1494)
Psi I (4238)
Psr I (3007)
Pvu I (6354)
Sbf I (1150)
Sci I (3541)
Sfo I (948)
Sgr AI (2423)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6788)
Stu I (4636)
Xho I (3539)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-33. TS45_delRBS.
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GVTS45
6942 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (949)
SU-CTD (2465)
SU-PRR (2328)
SU-RBD (1640)M oM LV(7776)/pcDNA3 del  Neo(938) junction (3541)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa  72-85) (1853)
SV40 ORI
2 extra nt after ligation (gc) (1163)
Perfect Splice Donor (1149)
Perfect Splice Acceptor (1237)
filled MluI site (228)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding s ite
Aar I (1156)
Afl III (5127)
Alo I (4185)
Avr II (4673)
Bam HI (2302)
Bbe I (953)
Bbr 7I (3840)
Bbs I (3835)
Bcl I (3633)
Bpl I (4640)
Bsa BI (3556)
Bsm I (3430)
Bsp EI (2274)
Bst EII (1688)
Bst Z17I (4748)
Cla I (3440)
Eag I (3569)
Eco RI (3542)
Fsp I (6242)
Kas I (949)
Mfe I (162)
Nae I (4043)
Nar I (950)
Nde I (488)
Ngo MIV (4041)
Not I (3569)
Nru I (209)
Pci I (5127)
Pfl MI (2427)
Pml I (1497)
Psi I (4274)
Psr I (3043)
Pvu I (6390)
Sbf I (1153)
Sci I (3577)
Sfo I (951)
Sgr AI (2459)
Sna BI (594)
Sse 8647I (1420)
Ssp I (6824)
Stu I (4672)
Xho I (3575)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-34. GVTS45.
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GVTS45 del RBS
6909 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
Repeat Region (949)
SU-CTD (2432)
SU-PRR (2295)
SU-RBD (1640)
M oM LV(7776)/pcDNA3 del Neo(938) junction (3508)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (1853)
SV40 ORI
2 extra nt after ligation (gc) (1163)
Perfect Splice Donor (1149)
Perfect Splice Acceptor (1237)
filled MluI site (228)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1156)
Alo I (4152)
Avr II (4640)
Bam HI (2269)
Bbe I (953)
Bbr 7I (3807)
Bbs I (3802)
Bcl I (3600)
Bpl I (4607)
Bpu 10I (181)
Bsa BI (3523)
Bsm I (3397)
Bsp EI (2241)
Bst EII (1688)
Bst Z17I (4715)
Cla I (3407)
Eag I (3536)
Eco RI (3509)
Fsp I (6209)
Kas I (949)
Mfe I (162)
Mlu I (1855)
Nae I (4010)
Nar I (950)
Nde I (488)
Ngo MIV (4008)
Not I (3536)
Nru I (209)
Pci I (5094)
Pfl MI (2394)
Pml I (1497)
Psi I (4241)
Psr I (3010)
Pvu I (6357)
Sbf I (1153)
Sci I (3544)
Sfo I (951)
Sgr AI (2426)
Sna BI (594)
Sse 8647I (1420)
Ssp I (6791)
Stu I (4639)
Xho I (3542)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-35. GVTS45_delRBS.
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TS45/HBS-1
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-1 (E127K) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-36. TS45/HBS-1.
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TS45/HBS-2
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-2 (E127R) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-37. TS45/HBS-2.
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TS45/HBS-3
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-3 (E127H) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-38. TS45/HBS-3.
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TS45/HBS-4
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-4 (a ll B=K) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-39. TS45/HBS-4.
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TS45/HBS-5
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-5 (a ll B=R) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-40. TS45/HBS-5.
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TS45/HBS-6
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-6 (a ll B=RorH) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-41. TS45/HBS-6.
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TS45/HBS-7
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-7 (a ll B=KorH) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537) SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Aar I (1153)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bpl I (4637)
Bsa BI (3553)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-42. TS45/HBS-7.
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TS45/HBS-8
6939 bp
ENV
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-8 (a ll B=A) (2000)
Repeat Region (946)
M oM LV Env(7776)/pcDNA3 del  Neo(938) junction (3537)
SU-RBD (1637)
SU-PRR (2325)
SU-CTD (2462)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter putative RBS (env aa 72-85) (1850)
SV40 ORI
2 extra nt after ligation (gc) (1160)
Perfect Splice Donor (1146)
Perfect Splice Acceptor (1234)
HBS Wobble Mutations (1964)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Afe I (2021)
Alo I (4182)
Avr II (4670)
Bam HI (2299)
Bbe I (950)
Bbr 7I (3837)
Bbs I (3832)
Bcl I (3630)
Bmt I (2026)
Bpl I (4637)
Bsa BI (3553)
Bsg I (1990)
Bsm I (3427)
Bsp EI (2271)
Bst EII (1685)
Bst Z17I (4745)
Cla I (3437)
Eag I (3566)
Eco RI (3539)
Fsp I (6239)
Kas I (946)
Mfe I (162)
Mlu I (229)
Nae I (4040)
Nar I (947)
Nde I (485)
Ngo MIV (4038)
Nhe I (2022)
Not I (3566)
Nru I (209)
Pci I (5124)
Pfl MI (2424)
Pml I (1494)
Psi I (4271)
Psr I (3040)
Pvu I (6387)
Sbf I (1150)
Sci I (3574)
Sfo I (948)
Sgr AI (2456)
Sna BI (591)
Sse 8647I (1417)
Ssp I (6821)
Stu I (4669)
Xho I (3572)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-43. TS45/HBS-8.
 
 
752
11807 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7107)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8375)
SU-RBD (6474)
SU-PRR (7162)
SU-CTD (7299)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Bst Z17I (9613)
Eco RI (8407)
Fal I (3673)
Fsp I (11107)
Hin dIII (5493)
Mlu I (229)
Nae I (8908)
Ngo MIV (8906)
Not I (8434)
Pci I (9992)
Pml I (6331)
Psh AI (2025)
Psi I (9139)
Psr I (7877)
Sac II (5551)
Sfi I (5988)
Sgr AI (7293)
Sna BI (591)
Ssp I (11689)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-44. 752.
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FL-28
11831 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7131)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8399)
SU-RBD (6474)
SU-PRR (7186)
SU-CTD (7323)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Sst/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8431)
Fsp I (11131)
Hin dIII (5493)
Nae I (8932)
Ngo MIV (8930)
Not I (8458)
Pci I (10016)
Pml I (6331)
Psh AI (2025)
Psi I (9163)
Psr I (7901)
Sac II (5551)
Sfi I (5988)
Sgr AI (7317)
Sna BI (591)
Ssp I (11713)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-45. FL-28.
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LR51A
11831 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7131)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8399)
SU-RBD (6474)
SU-PRR (7186)
SU-CTD (7323)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
RGD/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8431)
Fal I (3673)
Fsp I (11131)
Hin dIII (5493)
Nae I (8932)
Ngo MIV (8930)
Not I (8458)
Pci I (10016)
Pml I (6331)
Psh AI (2025)
Psi I (9163)
Psr I (7901)
Sfi I (5988)
Sgr AI (7317)
Sna BI (591)
Ssp I (11713)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-46. LR51A.
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FL67
11843 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7143)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8411)
SU-RBD (6474)
SU-PRR (7198)
SU-CTD (7335)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-Bom-1/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8443)
Fal I (3673)
Fsp I (11143)
Hin dIII (5493)
Nae I (8944)
Ngo MIV (8942)
Not I (8470)
Pci I (10028)
Pml I (6331)
Psh AI (2025)
Psi I (9175)
Psr I (7913)
Sac II (5551)
Sfi I (5988)
Sgr AI (7329)
Sna BI (591)
Ssp I (11725)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-47. FL67.
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FL68
11855 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut si te (7155)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8423)
SU-RBD (6474)
SU-PRR (7210)
SU-CTD (7347)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-Bom-2/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8455)
Fsp I (11155)
Nae I (8956)
Ngo MIV (8954)
Not I (8482)
Pci I (10040)
Pml I (6331)
Psh AI (2025)
Psi I (9187)
Psr I (7925)
Sac II (5551)
Sfi I (5988)
Sgr AI (7341)
Sna BI (591)
Ssp I (11737)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-48. FL68.
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FL59
11828 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7128)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8396)
SU-RBD (6474)
SU-PRR (7183)
SU-CTD (7320)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Cys-RGD/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Bst Z17I (9634)
Eco RI (8428)
Fal I (3673)
Fsp I (11128)
Hin dIII (5493)
Nae I (8929)
Ngo MIV (8927)
Not I (8455)
Pci I (10013)
Pml I (6331)
Psh AI (2025)
Psi I (9160)
Psr I (7898)
Sfi I (5988)
Sgr AI (7314)
Sna BI (591)
Ssp I (11710)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-49. FL59.
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LS53
11822 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7122)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8390)
SU-RBD (6474)
SU-PRR (7177)
SU-CTD (7314)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
SP/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8422)
Fal I (3673)
Fsp I (11122)
Hin dIII (5493)
Nae I (8923)
Ngo MIV (8921)
Not I (8449)
Pci I (10007)
Pml I (6331)
Psh AI (2025)
Psi I (9154)
Psr I (7892)
Sac II (5551)
Sfi I (5988)
Sgr AI (7308)
Sna BI (591)
Ssp I (11704)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-50. LS53.
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LN54
11825 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7125)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8393)
SU-RBD (6474)
SU-PRR (7180)
SU-CTD (7317)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
NT/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8425)
Fal I (3673)
Fsp I (11125)
Hin dIII (5493)
Nae I (8926)
Ngo MIV (8924)
Not I (8452)
Pci I (10010)
Pml I (6331)
Psh AI (2025)
Psi I (9157)
Psr I (7895)
Sfi I (5988)
Sgr AI (7311)
Sna BI (591)
Ssp I (11707)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-51. LN54.
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LO49
11807 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7107)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8375)
SU-RBD (6474)
SU-PRR (7162)
SU-CTD (7299)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
OT/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Bst Z17I (9613)
Eco RI (8407)
Fal I (3673)
Fsp I (11107)
Hin dIII (5493)
Mlu I (229)
Nae I (8908)
Ngo MIV (8906)
Not I (8434)
Pci I (9992)
Pml I (6331)
Psh AI (2025)
Psi I (9139)
Psr I (7877)
Sac II (5551)
Sfi I (5988)
Sgr AI (7293)
Sna BI (591)
Ssp I (11689)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-52. LO49.
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LB56-5
11831 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7131)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8399)
SU-RBD (6474)
SU-PRR (7186)
SU-CTD (7323)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Bom/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Eco RI (8431)
Fal I (3673)
Fsp I (11131)
Hin dIII (5493)
Nae I (8932)
Ngo MIV (8930)
Not I (8458)
Pci I (10016)
Pml I (6331)
Psh AI (2025)
Psi I (9163)
Psr I (7901)
Sac II (5551)
Sfi I (5988)
Sgr AI (7317)
Sna BI (591)
Ssp I (11713)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-53. LB56-5.
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LE50
11843 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
Splice Donor (1148)
Splice Acceptor (6085)
Repeat Region (946)
Unique BspEI cut site (7143)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8411)
SU-RBD (6474)
SU-PRR (7198)
SU-CTD (7335)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
Endo/RBS (6687)
SV40 ORI
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA primer binding site
Variation 1 (2447)
Variation 2 (2853)
del Psi (1160)
Bbv CI (5393)
Blp I (4869)
Bsg I (3788)
Bsr GI (1519)
Bst Z17I (9649)
Eco RI (8443)
Fal I (3673)
Fsp I (11143)
Hin dIII (5493)
Nae I (8944)
Ngo MIV (8942)
Not I (8470)
Pci I (10028)
Pml I (6331)
Psh AI (2025)
Psi I (9175)
Psr I (7913)
Sac II (5551)
Sfi I (5988)
Sgr AI (7329)
Sna BI (591)
Ssp I (11725)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-54. LE50.
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GV752
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI filled MluI site (228)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Afl III (9995)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-55. GV752.
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GV752 del RBS
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS (6807)
pro-tRNA primer binding site (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI filled MluI site (228)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  protein)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-56. GV752_delRBS.
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GV752/HBS-1
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-1 (E127K) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-57. GV752/HBS-1.
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GV752/HBS-2
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-2 (E127R) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-58. GV752/HBS-2.
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GV752/HBS-3
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-3 (E127H) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-59. GV752/HBS-3.
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GV752/HBS-4
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-4 (a ll  B=K) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-60. GV752/HBS-4.
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GV752/HBS-5
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-5 (a ll  B=R) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-61. GV752/HBS-5.
126 
 
 
GV752/HBS-6
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-6 (a ll B=RorH) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-62. GV752/HBS-6.
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GV752/HBS-7
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-7 (a ll B=KorH) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-63. GV752/HBS-7.
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GV752/HBS-8
11810 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-8 (a ll  B=A) (6840)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut site (7110)
M oM LV(7775)/pcDNA3 del Neo(907) junction (8378)
SU-RBD (6477)
SU-PRR (7165)
SU-CTD (7302)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 PromoterSp6 Prom oter
putative RBS (env aa 72-85) (6690)
SV40 ORI
HBS Wobble Mutations (6804)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
pro-tRNA prim er binding site
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Aar I (6858)
Afe I (6861)
Bbv CI (5396)
Blp I (4872)
Bmt I (6866)
Bsr GI (1522)
Bst Z17I (9616)
Eco RI (8410)
Fal I (3676)
Fsp I (11110)
Hin dIII (5496)
Nae I (8911)
Ngo MIV (8909)
Nhe I (6862)
Not I (8437)
Pci I (9995)
Pml I (6334)
Psh AI (2028)
Psi I (9142)
Psr I (7880)
Sac II (5554)
Sfi I (5991)
Sgr AI (7296)
Sna BI (594)
Ssp I (11692)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-64. GV752/HBS-8.
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GV752 del RBS/HBS-1
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-1 (E127K) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-65. GV752_delRBS/HBS-1.
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GV752 del RBS/HBS-2
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-2 (E127R) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like protein)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-66. GV752_delRBS/HBS-2.
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GV752 del RBS/HBS-3
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-3 (E127H) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  protein)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-67. GV752_delRBS/HBS-3.
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GV752 del RBS/HBS-4
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-4 (a ll B=K) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-68. GV752_delRBS/HBS-4.
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GV752 del RBS/HBS-5
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-5 (a ll B=R) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-69. GV752_delRBS/HBS-5.
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GV752 del RBS/HBS-6
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-6 (a ll B=RorH) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-70. GV752_delRBS/HBS-6.
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GV752 del RBS/HBS-7
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-7 (a ll  B=KorH) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA
CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
HBS Wobble Mutations (6771)
Conflict 1
p15 Matrix
p12
p30 Capsid
p10 NC (histone-like  prote in)
POL
gp70 SU
p15e TM
R-peptide
Variation 1 (2450)
Variation 2 (2856)
del Psi (1163)
Bbv CI (5396)
Blp I (4872)
Bsg I (3791)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-71. GV752_delRBS/HBS-7.
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GV752 del RBS/HBS-8
11777 bp
GAG
ENV
PRO
RT
IN
5'-LTR
part of UTR-3' (8213-8264)
HBS-8 (a ll  B=A) (6807)
pro-tRNA primer binding si te (1094)
Splice Donor (1151)
Splice Acceptor (6088)
Repeat Region (949)
Unique BspEI cut si te (7078)
M oM LV(7775)/pcDNA3 del Neor(907) junction (8345)
SU-CTD (7269)
SU-PRR (7132)
SU-RBD (6477)
pcDNA3 del Neo(893)/M oM LV(8213) junction (
AMPr
BGH pA CMV prom oter
T7 Promoter
Sp6 Prom oter
del  RBS (6690)
SV40 ORI
p10 NC (histone-like  prote in)
Variation 2 (2856)
137 
HBS Wobble Mutations (6771)
Conflict 1
del Psi (1163)
Variation 1 (2450)
p15 Matrix
p30 Capsid
p12
POL
p15e TM
gp70 SU
R-peptide
Aar I (6825)
Afe I (6828)
Bbv CI (5396)
Blp I (4872)
Bmt I (6833)
Bsr GI (1522)
Bst Z17I (9583)
Eco RI (8377)
Fal I (3676)
Fsp I (11077)
Hin dIII (5496)
Mlu I (6692)
Nae I (8878)
Ngo MIV (8876)
Nhe I (6829)
Not I (8404)
Pci I (9962)
Pml I (6334)
Psh AI (2028)
Psi I (9109)
Psr I (7847)
Sac II (5554)
Sfi I (5991)
Sgr AI (7263)
Sna BI (594)
Ssp I (11659)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C-72. GV752_delRBS/HBS-8.
Vita 
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